Aletho News

ΑΛΗΘΩΣ

The Sordid History of the CIA – Part 3

Tales of the American Empire | April 23, 2026

Tales of the American Empire produces short historical videos about the American empire, like the “Sordid History of the CIA”. The first two parts are linked in the description. Most viewers are interested in the American CIA, so this is another episode about videos detailing the evils of the CIA. Some CIA officers work with murderous dictators and criminal organizations involved in the drug trade, arms dealing, and government contract fraud. These evil deeds are sometimes uncovered by the media but receive little attention. There are YouTube videos that provide insight into covert CIA operations. This is far too much material to condense into a short video. Here is a quick review of more great YouTube videos about the CIA with a link to them below. If the link no longer works, the content has been removed. Two videos from the first part of this series have since disappeared. They may be found on smaller video hosting websites like Rumble, Bitchute, or Odyssey.

___________________________________________

Related Tale: “The Sordid History of the CIA”;    • The Sordid History of the CIA  

Related Tale: “The Sordid History of the CIA – Part 2”;    • The Sordid History of the CIA – Part 2  

“The 9/11 Commission Was A FRAUD” – Curt Weldon EXPOSES CIA Cover-Up, Able Danger & Deleted Evidence”; Valuetainment; May 14, 2025;    • “The 9/11 Commission Was A FRAUD” – Curt W…  

“Lee Harvey Oswald was a Patsy”; Tales; July 3, 2025;    • Lee Harvey Oswald was a Patsy  

“Prof. Jeffrey Sachs: Does the CIA Destabilize the World?”; Judging Freedom; February 14, 2024;    • Prof. Jeffrey Sachs: Does The CIA Destabil…  

“The Illusion Called South Vietnam”; Tales; August 3, 2019;    • The Illusion Called South Vietnam  

“Romania’s silent coup. EU/NATO tries to stop Georgescu”; The Duran; January 17, 2025;    • Romania’s silent coup. EU/NATO tries to st…  

“Operation Red Rock in Cambodia”; Tales; November 7, 2024;    • Operation Red Rock in Cambodia  

“Trump/Musk Attack CIA Fronts USAID & NED”; Mike Benz interview; Glenn Greenwald; February 4, 2025;    • Trump/Musk Attack CIA Fronts USAID & NED: …  

“The 1974 CIA Coup in the United States”; Tales; June 8, 2023;    • The 1974 CIA Coup in the United States  

“Former CIA Officer Exposes the Shadow Government”; Candace Owens; November 8, 2024;    • Former CIA Officer Exposes The Shadow Gove…  

“The American Colony Called Germany”; Tales; December 22, 2022;    • The American Colony Called Germany  

“They’re About to Change Everything and You Won’t Even Notice”; Whitney Webb interview; Investigative Insights TV; January 26, 2026;    • Video  

“CIA Coup in Kiev”; Tales; March 2, 2023;    • The Anglo-American War on Russia – Part Fi…  

Tales’ playlist: “The CIA”;    • The CIA   TAGS:

April 24, 2026 Posted by | Deception, Timeless or most popular, Video, War Crimes | , | Comments Off on The Sordid History of the CIA – Part 3

When It Comes to Using Proxies, The US Far Surpasses Iran as a Sponsor of Terrorism

By Larry C. Johnson | SONAR21 | April 24, 2026 

I have previously addressed the lie that Iran is the number one sponsor of terrorism. Now I want to look specifically at the question of how many Americans, both civilian and military, have been killed by proxies who have received assistance from Iran. I will flip the script… How many Iranians, civilian and military, have been killed by US proxies? The numbers are staggering. US proxies have killed almost 28,000 times the number of Iranians than Iranian proxies have killed Americans. These numbers come primarily from US Department of Justice indictments, State Department reports, American Jewish Committee (AJC), and compiled victim databases.

The principal Iranian proxies routinely identified in US government reports on terrorism are Hamas, Hezbollah, and a variety of Iraqi-Shia groups. If I used the strict definition of terrorism — i.e., the use of violence against civilians for political purposes — the number of actual terrorist deaths from Iranian proxies would be less than 300 since 1979. If I relied only on the strict definition, I would exclude all attacks on military targets. However, since the US statistics on terrorism include the 1983 bombing of the US Marines barracks in Lebanon and the roadside bombs targeting US forces in Iraq from 2003 -2011, I am including the military fatalities for both sides.

HAMAS

At least 60–70 Americans (including dual US-Israeli citizens) have been killed in attacks attributed to or carried out by Hamas since its founding in 1987. This is an approximate total based on US government, DOJ, and research compilations. The vast majority occurred on or after October 7, 2023.

October 7, 2023 Attack (the single deadliest incident)

43–46 Americans killed: (US Department of Justice indictment of Hamas leaders in 2024 confirmed at least 43; some sources, including the State Department, cite 46). These numbers include dual US-Israeli citizens murdered at kibbutzim, the Nova music festival, and other sites near Gaza.

Several additional Americans were taken hostage, with some (e.g., Hersh Goldberg-Polin) died in captivity as a result of Israel’s unconstrained bombing of Gaza.

Pre-October 7 Attacks (1987–2023)

Hamas carried out or claimed responsibility for numerous suicide bombings, shootings, and other attacks during the First and Second Intifadas and subsequent periods that resulted in the deaths of roughly 15–25 Americans, based on cross-referenced State Department chronologies and victim lists (exact counts vary slightly due to dual citizenship and attribution debates). Documented American deaths include:

2002 Hebrew University bombing: (Jerusalem): 5 Americans killed.

2003 Jerusalem bus bombing: 5 Americans killed. Other notable incidents (Second Intifada era, 2000–2005): Americans killed in attacks such as the Sbarro pizzeria bombing, Park Hotel Passover bombing, and various bus bombings (e.g., Alan Beer, Malka Roth, and others).

Earlier attacks (1990s): Smaller numbers, including incidents like the 1996 Jerusalem bus bombing (3 Americans) and others. Scattered additional deaths in the 1990s–2010s from stabbings, shootings, and bombings.

HEZBOLLAH

At least 270–300+ Americans (including service members and civilians, plus some dual U.S.-Israeli citizens) have been killed in attacks attributed to or carried out by Hezbollah (or its direct precursors like Islamic Jihad Organization) since its formation in 1982.

Major Incidents and Breakdown

1983 Beirut Attacks (the deadliest period):

April 18, 1983: U.S. Embassy bombing in Beirut — 17 Americans killed (including 8 CIA personnel).

October 23, 1983: U.S. Marine barracks bombing in Beirut — 241 Americans killed (220 Marines, 18 Navy sailors, 3 Army soldiers). This remains the single deadliest attack on U.S. Marines since Iwo Jima and the largest loss of American life to Hezbollah.

September 20, 1984: U.S. Embassy annex bombing in Beirut — 2 Americans killed.

Other Notable Attacks:

1980s hostage crisis and related violence: Several Americans were kidnapped and murdered, including CIA station chief William Buckley (1984–1985) and U.S. Marine Colonel William Higgins (kidnapped 1988, murdered 1989).

Scattered attacks in the 1980s–2000s: Additional deaths from hijackings (e.g., TWA Flight 847 in 1985, where U.S. Navy diver Robert Stethem was murdered), bombings, and operations in Iraq (Hezbollah-trained Shiite militias targeting U.S. forces post-2003).

The key take away from this data is that Hezbollah stopped attacking US targets in the 1990s and was not the face of Islamic extremism. Hezbollah focused its energy on attacking Israeli military targets.

OTHER IRANIAN PROXIES

At least 620–650+ Americans (mostly U.S. service members, plus some contractors and civilians) have been killed in attacks by Iranian proxies excluding Hamas and Hezbollah since 1979. The vast majority of these deaths occurred in Iraq during the 2003–2011 period.

Primary Figure: Iraqi Shiite Militias (2003–2011)

At least 603 U.S. troops were killed by Iran-backed Shiite militias in Iraq between 2003 and 2011, according to the U.S. Department of Defense/Pentagon assessment. These militias include groups such as Kata’ib Hezbollah (KH), Asa’ib Ahl al-Haq (AAH), the Badr Organization, Harakat Hezbollah al-Nujaba, and others.

Iran provided advanced weaponry (especially explosively formed penetrators or EFPs), training, and direction via the IRGC Quds Force. This accounted for roughly 17% of all U.S. combat deaths in Iraq during that period.

US PROXY TERRORISM AGAINST IRAN

Now I want to address the antagonism of the US towards Iran, where multiple US presidents used proxies to attack Iran. Let’s start with the case of Iraq… In 1980, the CIA, acting under a finding signed by President Jimmy Carter, began providing support to Saddam Hussein with the goal of Iraq launching an attack on Iran. Saddam attacked Iran in September 1980. When the Reagan administration took power in January 1981, the support for Iraq increased dramatically with the US supplying precursor chemicals that were used to make chemical weapons, financial aid, and classified intelligence that was routinely shared with the Iraqi General Staff. The CIA handled the task of sharing intelligence until 1986 when, as a result of the Iran/Contra revelations, Saddam refused to deal anymore with the CIA and would only accept assistance from the US military. The task of carrying US intelligence to Iraq, starting in 1987, was given to Colonel Walter Patrick Lang aka Pat. Pat, who is now deceased, was a close friend of mine for more than 20 years.

Using the same standard of blaming Iran for the actions of Hezbollah, the US merits blame for its prolific support for Saddam Hussein during the war on Iran. Estimates of Iranian deaths in the Iran-Iraq War (1980–1988, also known as the First Gulf War) vary widely due to the fog of war, propaganda from both sides, and limited transparent records. Iraq, under Saddam Hussein, launched the war with a surprise invasion of Iran on September 22, 1980. The US provided direct, covert support to Iraq (intelligence, economic aid, and allowing allies to supply weapons) during much of the conflict.

Iranian military deaths, based on a 2013 systematic review in the Iranian Journal of Public Health (based on Iranian records), put the figure at 188,015 to 217,489 killed (roughly 70 people per day over 2,887 days of war). Iranian civilian deaths, according to Western/CIA estimates, are estimated to be 50,000–60,000 dead.

MEK

Besides using Iraq as a weapon against Iran, the US also took a page out of Saddam Hussein’s playbook. Saddam provided sanctuary and financiing, along with weapons, to the Mujahedin-e Khalq (MEK). They not only fought alongside Saddam’s forces in the war with Iran but, after the war, continued to carry out terrorist attacks inside Iran.

Following the US-led invasion of Iraq in March 2003, Coalition forces bombed MEK bases (the group had been allied with Saddam Hussein). The MEK surrendered its heavy weapons and concentrated at Camp Ashraf. n 2004, Secretary of Defense Donald Rumsfeld designated MEK members as “protected persons” under the Fourth Geneva Convention. US forces provided security at the camp, shielding them from Iraqi forces and preventing repatriation to Iran.

Starting around 2004–2005, the US provided clandestine support to the MEK as part of broader efforts to pressure Iran’s nuclear program and regime. This included intelligence cooperation, funding channels to dissident groups, and operational assistance. According to Pulitzer Prize-winning journalist Seymour Hersh (reporting in The New Yorker in 2012), the US Joint Special Operations Command (JSOC) conducted secret training of MEK operatives at a facility in Nevada (Department of Energy’s Nevada National Security Site) beginning in 2005. Training covered communications, cryptography, small-unit tactics, weaponry, and other special operations skills. This reportedly continued into 2007 (or possibly later).

Funds were covertly passed to the MEK and other Iranian dissident groups for intelligence collection inside Iran and anti-regime activities. The MEK supplied intelligence on Iran’s nuclear sites (e.g., Natanz) and carried out CIA sponsored operations, such as the assassination of Iranian nuclear scientists. This support occurred even while the MEK remained on the US FTO list, reflecting internal US government tensions (e.g., Pentagon vs. State Department).

In September 2012, Secretary of State Hillary Clinton removed the MEK from the FTO list, citing its renunciation of violence and cooperation on relocation. This enabled greater political and logistical support for resettling members… many eventually went to Albania where they continued to receive support and training from the CIA.

The Iranian government claims that the Mujahedin-e Khalq (MEK) has killed more than 12,000 to 17,000 Iranians through terrorist attacks, assassinations, bombings, and armed operations since the early 1980s. This is the most frequently cited figure in Iranian official statements, state media, and court proceedings.

Hell, MEK alone has killed 12 to 17 times more Iranians than Iranian proxies have killed Americans. The numbers are not even close.

I want you to keep these numbers in mind the next time you hear some nitwit US politician or pundit ranting about Iranian sponsorship of terrorism. Hands down, the US is a bigger sponsor of terrorism than Iran by a fact of at least 12.

April 24, 2026 Posted by | Progressive Hypocrite, Timeless or most popular, Wars for Israel | , , , , | Comments Off on When It Comes to Using Proxies, The US Far Surpasses Iran as a Sponsor of Terrorism

Hidden history: How Mossad infiltrated Italy

By Kit Klarenberg | Al Mayadeen | April 24, 2026

Italian Prime Minister Giorgia Meloni’s April 13th announcement that Rome will suspend a longstanding defense agreement with “Israel” sent shockwaves throughout Europe. Historically, Italian governments – even when led by figures who abhor Zionism – have enjoyed constructive, close ties with Tel Aviv. Mossad and Rome’s security, intelligence, and military apparatus also have a long-running clandestine relationship. In fact, the entity’s putrid overseas spying, assassination, and sabotage nexus was effectively born in Italy and has wreaked havoc in the country ever since.

Details of how Zionist spies secured a firm foothold in Italy are provided in a fascinating paper by academic Massimiliano Fiore. Drawing on archival sources, he “traces the evolution of Israeli clandestine activity” in Rome, demonstrating how Zionist intelligence connivances were waged in and against the country even before the entity’s May 1948 founding and throughout the war of erasure against Palestine that subsequently erupted. Several case studies map how Mossad’s criminality evolved over time, growing ever bolder, while informing how the agency operates globally today.

The story begins in the wake of the United Nations General Assembly’s November 1947 Partition Plan, which granted Zionist colonizers 55% of Palestine’s territory. Arab states immediately began preparing to resist the entity’s construction, training soldiers in Palestine and neighbouring countries for the purpose. In response, “Israel’s” founder, David Ben-Gurion, issued a directive to Zionist paramilitary and intelligence factions to secure weapons for the impending genocidal war over Palestinian territory, while denying them to Arab forces.

Fiore records how the chief Mossad le-Aliyah Bet and Rekhesh – respectively, the spying and arms procurement wings of notorious Zionist paramilitary Haganah – immediately “established a sabotage unit in Rome that quickly became an operational hub of Israeli covert activity in Italy and across Europe.” Thereafter, Zionist operatives “exploited Italy’s political ambiguity and physical infrastructure to conduct a sustained campaign of sabotage and interception.” The academic dubs this covert contest on Italian soil “a secret front” in the 1948 war.

Rome’s ports and air and sea transport corridors “played a critical role in sustaining Israeli supply” of weapons for the 1948 war, while disrupting the flow of arms to Arab militaries. Moreover, Zionists “sought to shape the Mediterranean balance of power” for their own malign purposes. Their covert actions – “conducted under conditions of political tolerance and diplomatic constraint” – forged strong bonds with the Italian state, while supplanting Rome’s status “as a strategic bridge between Europe, North Africa, and the Middle East.”

The incipient Mossad’s cloak-and-dagger conniving in Italy had a devastating impact. A June 1948 CIA memo observed how the “European headquarters” of Zionist intelligence “operated under cover in Rome,” through which “clandestine transport of munitions by air” to Palestine was conducted with “the knowledge and collusion” of Italian authorities. Without European citizens, Arab governments, or the ‘international community’ noticing, Rome had been secretly transformed into an international nucleus of “illegal traffic in arms for the Jewish underground.”

‘Riskier measures’

Rewind to March 1948, Czechoslovakia’s government approved the delivery of 8,000 rifles, 200 machine guns, and six million rounds of ammunition to Syria. Set to sail next month on the Lino, a 450-ton Italian freighter, Zionist operatives were determined that the shipment would not reach West Asia. First, its passage was impeded by Haganah warning authorities in Rome that a ship laden with weapons was headed to Italy. Given the “charged political atmosphere” preceding the country’s election, officials quickly moved to impound the Lino.

On the night of April 10, a Zionist sabotage squad descended on the vessel and attached explosive charges before slipping away undetected. The ship sank without casualties or attribution. Per Fiore, the Italian media suggested weapons aboard might have been headed to local Communists, which “[deflected] suspicion away from Zionist involvement.” While a small operation, the Lino’s sinking was seismic. The effort “demonstrated how limited resources, local networks, and deniable maritime sabotage could produce disproportionate effects, disrupting adversary supply while avoiding interstate escalation.”

The Lino operation’s success prompted the formal establishment in May 1948 of a “Unit for the Sabotage of Enemy Supply in Europe,” headquartered in Rome. It rapidly became a “central hub for intelligence, logistics, and coordination” across Italy and Europe for Zionist spies. “Jewish operatives and instructors already active on the continent” joined its ranks, receiving training in all manner of skullduggery, assisted by Italian military and intelligence veterans. Among them were battle-hardened fascists, whose World War II experiences informed future Israeli operational practices.

Meanwhile, a Syrian initiative to recover the sunken Lino’s consignment was ongoing. The weapons and ammunition were successfully salvaged and repaired, then redirected to their original destination on a vessel called the Argiro. But Zionist spies were watching and intended to seize the shipment. Via bribery and elaborate deception, operatives infiltrated the ship’s crew, clearing the way for Zionists posing as a security escort to board the vessel while en route to West Asia. On August 21st, the Argiro was captured and directed to Palestine.

Five days later, Zionist naval forces commandeered the Argiro, seizing the materiel before sinking the ship outright. The lethal cargo reached Haifa four days later and was sent to Zionist militants fighting in al-Quds. The Italian crew was temporarily detained rather than killed or disappeared, although the captain died from tuberculosis in captivity before being returned home in any event, raising the spectre of an international incident erupting between the expanding settler colony and Rome.

Fiore notes the Argiro effort was an early example of “strategic appropriation” by Zionist spies, foreshadowing future operations in which “intelligence, deception, and procurement functioned as mutually reinforcing instruments.” This journalist has documented how a similar approach was applied in the early 1960s, during the entity’s criminal quest to clandestinely acquire nuclear weapons. Furthermore, Argiro’s takeover amply illustrated how Zionist agents in Italy were willing to undertake “progressively riskier measures,” which could cause tension with Rome. But the burgeoning Mossad had little to fear.

‘Diplomatic buffer’

In early 1949, Zionist militants attempted to blow up motor torpedo boats in an Italian shipyard that had been purchased by Egypt. Fiore records how the operation prioritized concealment and “strict deniability” to avoid “diplomatic repercussions” and benefited from an insider providing access to the site. However, the plot’s executors, led by an explosives specialist centrally involved in the Lino’s sinking, were caught in flagrante by local police. In June that year, the group’s leader was sentenced to three years in prison for possessing explosives.

This prompted “sustained diplomatic intervention” from the fledgling Zionist entity’s highest levels, resulting in the convicted agent being freed under a presidential pardon. A “calculated act of executive leniency,” the move set a precedent that endured for decades ever after, and may do so today. The same month the Zionist spies were busted, Italian premier Alcide De Gasperi granted local Mossad chief Ada Sereni informal carte blanche to conduct clandestine operations in her country.

Accordingly, Mossad activities not merely in Italy, but the world over, subsequently emphasized “deception, improvisation, and operational daring.” As long as the connivances of Zionist spies “remained beneath the threshold of public escalation,” authorities in Rome would “close one eye – preferably two.” It was the beginning of a policy of strategic ambiguity, whereby Italy sought to maintain amicable relations with the Arab and Muslim world and Tel Aviv simultaneously. It was hoped that Rome could avoid being dragged into the Palestinian issue, therefore preserving “political equilibrium”.

Under the auspices of this clandestine concord, the Zionist entity benefited enormously from “selective enforcement” of local laws, political pardons if its operatives and/or schemes were exposed, and other indulgences. Mossad could thus exploit Rome “as a transit corridor, logistical base, and diplomatic buffer.” However, Tel Aviv routinely flouted the terms of this dispensation, gravely compromising the country’s “political equilibrium”. For one, “Israel” couldn’t tolerate Palestinian Resistance fighters and groups smuggling weapons or traveling without hindrance through Italy or enjoying political protection locally.

This blind eye to Palestinian Resistance became known as the “Lodo Moro” agreement, so-called because it was instituted by veteran Italian statesman and former prime minister Aldo Moro. Mossad sought to harshly penalize Rome for this leniency toward the Palestinian cause. Questions abound over Zionist involvement in numerous high-profile acts of terror perpetrated in Italy subsequently, such as the August 1980 bombing of Bologna Centrale railway station, which killed 85 people and wounded over 200, and political assassinations – including Moro’s own.

An ardent anti-Zionist, Moro was ostensibly kidnapped by the Red Brigades, a left-wing guerrilla movement, in March 1978. He was killed after 55 days in captivity. Numerous knowledgeable sources have testified to successive parliamentary inquiries and official investigations over the decades about how Mossad infiltrated and assisted the Red Brigades, seeking to influence the group’s activities from inception. Moreover, there was likewise a little-known but hugely impactful Zionist hand in the notorious CIA and MI6-run Operation Gladio from the very beginning.

Chaos unleashed by Gladio greatly furthered Mossad’s quest to destabilize Italy, in service of boosting “Israel’s” financial, military, and political support from the US. There is little chance of Tel Aviv’s geopolitical position being challenged by Rome today. Yet, incidents such as the mysterious late March attack on an Italian oil pipeline raise obvious questions about whether the local Zionist wrecking network constructed decades ago remains in place and still sends incendiary warnings to the country’s government not to step too far out of line.

April 24, 2026 Posted by | Deception, Ethnic Cleansing, Racism, Zionism, Timeless or most popular | , , , , | Comments Off on Hidden history: How Mossad infiltrated Italy

Promises, pressure, pullout: Why US nuclear talks with Iran were never about a deal

By Mohammad Molaei | Press TV | April 24, 2026

For over two decades, US-Iran nuclear negotiations have been wrapped in secrecy and sold as a mechanism for reducing tensions. Yet a closer examination reveals a far different reality.

Negotiations were never intended to deliver a just or lasting solution. As the evidence suggests, they were simply a tool, a mechanism for the United States to maintain pressure on Iran while preserving the facade of diplomacy.

From the early 2000s through the signing of the nuclear deal in 2015 and its eventual unraveling three years later, the nuclear negotiation process has been defined by a single, consistent reality: the United States has never been a trustworthy or reliable partner at the table, and the negotiations have never produced the outcomes that were initially expected.

Roots of the crisis

The roots of the crisis, according to the evidence examined by this writer, trace back to 2002, when peaceful energy-centric nuclear facilities were unveiled in the central Iranian cities of Natanz and Arak. Western governments seized on these as evidence of so-called “military ambition.”

Yet Iran made clear from the very beginning that its nuclear program was peaceful and fully within its rights under Article IV of the Treaty on the Non-Proliferation of Nuclear Weapons (NPT). What began as a technical issue concerning safeguards compliance soon metastasized into a broader geopolitical confrontation.

This transformation did not occur because of any real diversion in Iran’s program. Rather, the nuclear dossier offered the United States and its allies a convenient pretext to sustain strategic pressure against a state that refused to submit to Western domination in West Asia.

This pattern emerged early in the negotiations with the so-called EU-3 – France, Germany, and the United Kingdom – culminating in the Saadabad Declaration of 2003.

Seeking to prevent escalation, Iran voluntarily halted uranium enrichment and, as a counterpart, accepted the Additional Protocol, granting the IAEA expanded access to nuclear sites. These steps went well beyond Iranian legal requirements and were widely regarded as a significant act of goodwill.

Yet rather than reciprocating with tangible concessions or normalization, Western powers seized on the suspension to demand even more radical measures. The voluntary and provisional nature of Iran’s commitments was gradually reframed by European negotiators into open-ended constraints.

Iran resuming parts of nuclear program

The asymmetry of expectations became impossible to ignore, and the fragile trust that had been built soon evaporated. By 2005, it was clear that the West’s objective was not transparency but permanent restriction.

In defense of its sovereign rights, Iran resumed parts of its nuclear program. That dynamic would define the next two decades: every Iranian show of restraint was answered not with reciprocity, but with escalating demands and mounting pressure.

The next turning point came in 2006, when Iran’s nuclear file was referred to the United Nations Security Council. The crisis was now internationalized.

Over the following years, successive resolutions imposed escalating sanctions on Iran’s nuclear and missile programs, arms transfers, and froze the assets of individuals and organizations.

Alongside these multilateral measures, the United States intensified its unilateral sanctions regime – particularly between 2010 and 2013 – when comprehensive financial and energy sanctions effectively amounted to a total embargo on Iran.

Legislation such as the Comprehensive Iran Sanctions, Accountability, and Divestment Act (CISADA), combined with sanctions targeting Iran’s central bank and oil exports, succeeded in isolating the Iranian economy from global finance.

By this stage, the nuclear issue had clearly ceased to be a technical file. It had become an instrument of economic warfare, designed to coerce Iran into altering not only its nuclear policy but its entire strategic orientation.

JCPOA and how it materialized

It was against this backdrop of relentless pressure that the JCPOA was reached in 2015, today hyped as one of the most comprehensive nonproliferation agreements in diplomatic history.

Under the controversial deal, Iran accepted unprecedented restrictions on its nuclear program: stringent caps on enrichment levels, a dramatic reduction of its uranium stockpile, and full IAEA surveillance. These were not hollow concessions but a verifiable rollback of Iran’s nuclear capabilities, offered in exchange for sanctions relief and economic integration.

Moreover, successive IAEA reports from 2016 to 2018 confirmed Iran’s full compliance – a fact that vindicates Iran’s consistent claim that its nuclear program was always peaceful.

Nevertheless, despite Iran’s full cooperation, the expected benefits of the JCPOA never materialized in any meaningful way. Structural barriers within the US sanctions architecture deterred international businesses and financial institutions from engaging with Iran, even after some restrictions were formally lifted.

This systematic failure to deliver tangible outcomes pointed to a deeper problem: the United States had no intention of providing genuine economic relief, preferring to maintain its sanctions leverage despite being a signatory to the deal.

Trump’s withdrawal from JCPOA

The truth became undeniable in May 2018, when the US administration unilaterally withdrew from the JCPOA – even as Iran remained in full compliance – and reimposed comprehensive sanctions under the banner of so-called “maximum pressure.”

This not only erased any economic gains Iran might have realized but also demonstrated that any agreement with Washington was structurally unreliable and could be undone at any moment based on political whim.

The US withdrawal only deepened the cycle. As sanctions escalated and pressure mounted, Iran began scaling back its voluntary commitments under the JCPOA after a year of strategic restraint, invoking provisions that allowed for remedial action in the event of non-compliance by the other party.

These steps, including increased enrichment levels and advanced centrifuge research, were presented by Tehran as reversible measures, contingent on the restoration of sanctions relief.

Yet the West, instead of addressing the root cause of the crisis – the US violation of the agreement – once again focused its rhetoric on Iran’s nuclear activities. This inversion of cause and effect simply reset the familiar cycle of pressure and negotiation.

Limitations of the diplomatic process

The inherent limitations of the diplomatic process became clear during efforts to revive the deal through indirect Vienna negotiations starting in 2021. The core issues remained unresolved because talks focused merely on how to arrange a return to compliance.

Iran sought reasonable assurances that the US would not break its word again, along with economic compensation for its own compliance. Washington cited internal political and constitutional constraints as reasons such guarantees were impossible.

The resulting stalemate exposed a fundamental failure: the absence of any practical mechanism to ensure US promises are kept or prevent future violations, dooming any future settlement to the same cycle of disintegration.

The IAEA’s role has also come under scrutiny. Technical safeguards issues have repeatedly been pushed to the edge of a political flashpoint. Impartial compliance monitoring should be the agency’s mandate, yet on Iran, it has aligned with Western pressure, selectively raising issues at Iran’s expense – especially when geopolitical tensions peak.

This has reinforced the perception that the nuclear file is not technical but part of a larger pressure architecture, where institutional mechanisms are weaponized to justify more investigations and punishment.

Lessons from two decades of negotiations

The past two decades leave no room for doubt. The pattern is unmistakable: Iran can negotiate, compromise, and open up, only to face new demands, new sanctions, and shifting goalposts.

Every diplomatic phase has been followed not by resolution but by the reorganization of pressure in another form. This is not about miscalculations or technical differences. It is a chain of political choices in which diplomacy serves not as an end but as a means to gain advantage over Iran. The nuclear issue has become a scapegoat, not a genuine concern, but a tool to coerce and constrain an independent regional power.

The conclusion is inescapable. The technical dimension of Iran’s nuclear program has never been the real issue. Iran has submitted to one of the most invasive verification systems in history and has been repeatedly verified as peaceful.

The true obstacle is that the United States refuses to engage on terms of mutual respect, reciprocity, or long-term commitment. Washington always operates top-down, imposing conditions while reserving the right to walk away.

Under these conditions, nuclear negotiations with the US cannot produce a solution.

The process is fundamentally flawed and has been an absolute failure. And since Iran has already proven its program is peaceful, further talks are worthless – nothing more than pressure recycled as diplomacy.

The ongoing stalemate in the Islamabad talks is fundamentally due to Iran’s refusal to be dragged into a vicious cycle again. After emerging triumphant in the 40-day war, Iran is not willing to accept any of the US maximalist and unreasonable demands.

The nuclear file is effectively off the negotiating table, as the talks underway for nearly two decades have never been about a nuclear deal.

April 24, 2026 Posted by | Economics, Timeless or most popular, Wars for Israel | , , , | Comments Off on Promises, pressure, pullout: Why US nuclear talks with Iran were never about a deal

The First Photographs Ever Taken of Iran [1848-1858] by Colonel Luigi Pesce + Persepolis, Old World

Jarid Boosters | June 22, 2023

I’ve found an astounding collection of the very first photographs of Iran, all taken by Colonel Luigi Pesce of Naples, who was deployed to Iran in 1848, in charge of training Iran’s new infantry troops up to the Italian Standard. While stationed in Iran, Luigi Pesce gained an appreciation, some would say a love, for the ancient structures and artifacts he would come in contact with on a daily basis.

He decided to combine his new appreciation for Ancient Iran with his favorite hobby, which was the up-and-coming technology of photography. From 1848 through 1858, Luigi photographed the cities, monuments, and people of Iran. The photographs are very clear and detailed for the time. Today we will view his seldom seen, yet historically important collection in complete detail.

April 23, 2026 Posted by | Timeless or most popular, Video | | Comments Off on The First Photographs Ever Taken of Iran [1848-1858] by Colonel Luigi Pesce + Persepolis, Old World

The Voters’ Self-Induced Matrix

By Jeb Smith | The Libertarian Institute | April 20, 2026

In Collective Illusions: Conformity, Complicity, and the Science of Why We Make Bad Decisions, Professor Todd Rose explains that to belong to a group, people “keep twisting [themselves] into pretzels, trying to conform to what we falsely believe everyone else expects of us.” Seeking acceptance from the group, we conform in language, behavior, beliefs, and practices. As a result, we lose our individuality and aggregate into herds. Within our group we create an alternate reality to fit whichever collective mindset we attach ourselves to, and interpret the world through those lenses—our innate desire to belong overrides reality.

Rose says these illusions “have become a defining feature of our modern society.” In other words, the collectivist mindset is a great conduit for spreading illusions; thus, it is the politician’s favored form of governance.

Rose points to studies in psychology and neuroscience showing we delude ourselves into believing what the majority does, even if it is not what we desire or know to be accurate. Simple problems and even opinions over our favorite foods are affected by peer pressure. When we are isolated, we perform very well, but as part of a test group we often give the wrong answer to conform with the majority. We are not even doing so for acceptance; rather we delude ourselves, and scans of our brains show we actually agree with what is blatantly false. Even when separated from the other subjects (who would not know about our nonconformity), we still conform to the majority once their opinions are revealed to us. Yes, we change our opinions and beliefs to avoid being ostracized, but our brains will adjust our opinions to make us think we desire what the majority does. Rose wrote, “Our internal drive to follow others is so powerful that, if we are not careful, we end up tossing our own private judgment out the window.”

Our self-deception becomes worse when politics are intermingled. Studies show when we are emotionally invested, we unconsciously and even consciously avoid information refuting our position. Rose says when faced with a truth potentially disrupting our internal reality, our “illusion,” we “do everything we can to avoid looking it in the face.” Rose explains:

“When we feel emotionally attached to certain views…we end up using whatever proof we find to simply reinforce the persistent conclusions of our in-group…when membership becomes part of our identity we become protective of its worldview, which we have taken pains to reinforce. We can also become hostile towards people who are not in our group.”

When studies contrasted the two main policies dealing with a contested issue, people who held no opinion either way would change stance once it was revealed which one was “left” and which “right” (regardless of whether this was the case). They immediately identified with and accepted their preferred group’s stances. They were not just trying to fit in; they actually believed it was the correct way to handle the issue only after they had been told what was left and what was right. Again, the solution they adopted was not always their party’s solution; they only needed to believe it was, and it changed their thoughts.

Party affiliation heavily affects how people take on information and facts. They consistently twist the facts to “fit” the party and groupthink narrative. In their book Democracy for RealistsWhy Elections Do Not Produce Responsive Government, Professors Christopher H. Achen and Larry M. Bartels discovered, “Even on purely factual questions with clear right answers, citizens are sometimes willing to believe the opposite if it makes them feel better about their partisanship and vote choices.” Add on top of this our self-indoctrination, a media willing to lie and distort reality to paint the picture the customers desire, and you are ripe for the vast majority of voters to be misled. Voters create a self-made Matrix to live in.

We can follow the crowds and maintain our illusions, but I hope we decide truth is more vital than belonging to our cultural Matrix. When a large percentage of your society has adopted what was almost universally viewed as oppressive and unnatural worldwide for thousands of years, it’s time to ask if we are following along with an illusion.

April 22, 2026 Posted by | Book Review, Timeless or most popular | Comments Off on The Voters’ Self-Induced Matrix

The Gratitude of the Captured

An Essay on the Four Walls That Make the Injured Defend the Injury

Lies are Unbekoming | April 12, 2026

1. The Testimony That Should Not Exist

A woman films herself from a hospital bed. Her left side will not move. Her speech is slurred. She took the COVID vaccine three weeks earlier and had a stroke within days. The camera shakes because she is holding it with the hand that still works. And she says, into the lens, that she is glad she took it. Because it could have been worse.

By every ordinary standard of how people respond to injury, the woman in the bed should be angry. She should want to know what happened to her body, who gave her the injection, what was in it, why she was not warned. Instead she is defending the thing that harmed her, and she is doing it sincerely, from a bed she may never leave.

The pattern repeated at scale throughout 2021 and 2022. Myocarditis in young men, received with gratitude. Sudden hearing loss, received with gratitude. Menstrual disruption, miscarriage, Bell’s palsy, shingles, tinnitus, cognitive fog — received with gratitude. The injured gave television interviews thanking the health authorities. They wrote newspaper columns urging others to take the product that had injured them. They volunteered at vaccination centres. The more severe the injury, the more fervent the testimony.

The COVID case is the clearest and most recent instance of something older. Chemotherapy patients credit the treatment with saving them while enduring a devastation that is the treatment.¹ Flu shot recipients who get the flu report that the shot made it milder — a claim no one can check. Statin patients who develop muscle weakness, diabetes and cognitive decline continue taking the drug in gratitude for a heart attack that may never have been coming.² SSRI patients who cannot feel, cannot sleep without the pill, cannot leave the house without the prescription, describe the drug as having saved their lives.³ Parents whose children regress after vaccination defend the schedule that preceded the regression.

The gratitude is real. That is what makes it devastating. These patients are not lying or performing. They feel what they say they feel. They are captured, and the gratitude is what their captivity looks like when it speaks.

What follows rests on one claim. The phenomenon is an engineered room, not a cognitive error or a cultural drift. Four walls stand around the captured person, each sealing a different exit, built by identifiable actors serving documented interests. The same four walls stand around every major medical intervention of our time.

The essay names the walls, shows them at work across several medical domains, names their architects, and ends where it must — with the one act that brings them down.


2. The Sealed Room

Four walls hold the captured person in place. Each seals a different kind of escape. Together they form a room from which the individual patient, acting alone, cannot exit. The walls fail only at population scale, and only when enough of the captured begin to speak at once — a condition the later sections will examine.

Wall One — The Counterfactual Shield. The intervention is defended by an imagined alternative that never happened. It would have been so much worse without it. The worse outcome is unfalsifiable. It did not occur and cannot be examined. It exists only as a claim, and a claim that cannot lose.

Wall Two — Injury as Vindication. Actual harm from the intervention is converted, at the moment of appearance, into evidence the intervention was necessary. Side effects become signs the drug is working. Adverse events become imagine how bad it would have been otherwise. The harm is recruited to defend the thing that caused it.

Wall Three — The Sunk Cost Bind. The patient has submitted their body to risk, cost, violation. The psychological price of admitting the submission was unnecessary — or worse, actively harmful — is unbearable. Every subsequent piece of evidence gets reorganised to vindicate the original decision, and the reorganisation strengthens with time.

Wall Four — The Tribal Seal. The intervention is tribal. Taking it is membership. Refusing it is defection. Honest testimony about injury breaks ranks with the tribe that formed around the intervention. The social cost of speaking is exile, so the injured stay silent, or perform gratitude to remain inside.

The walls appear here in the order the captured person meets them psychologically. Wall One is intellectual — it is installed before anything happens, as the framing of the intervention. Wall Two is empirical — it activates when harm arrives, renaming it before the patient can. Wall Three is interior — it operates in the self, on the self. Wall Four is social, and it closes the last door, the one that opens onto another person.

The sections that follow examine the walls one by one, and then name the people who built them.


3. Wall One: The Counterfactual Shield

A man takes the COVID vaccine in March 2021 and does not get COVID for the next year. He reports that the vaccine worked.

A woman takes the same vaccine and gets COVID in September. She reports that the vaccine worked, because it would have been worse without it.

A second woman ends up in hospital with COVID in October. She reports that the vaccine worked, because without it she would have died.

A third ends up on a ventilator, survives, and reports that the vaccine saved her life.

Every possible outcome confirmed the intervention. The counterfactual shield is the mechanism that made this possible. For each real outcome, an imagined worse outcome was available for comparison, supplied by the same system that administered the injection. The patient did not compare their actual experience to another actual experience. They compared it to a hypothetical that could never be tested.

This is the structure of every statin prescription. The patient cannot feel cholesterol. They cannot feel the heart attack that did not occur. What they can feel is the muscle pain, the fatigue, the cognitive changes, the new diabetes — and they are told this is the acceptable cost of preventing something invisible. Prevention is the absence of an event, which means the benefit can never be observed, only claimed. Every year without a heart attack is credited to the drug. When a heart attack arrives anyway, the cardiologist explains how much worse it would have been.

The shield needs a particular statistical apparatus to stand. The patient does not invent the imagined alternative from nothing; it is delivered to them, precisely calibrated, by the medical literature. Relative risk reduction is the instrument. A drug that cuts heart attacks from two per hundred to one per hundred is described as producing a fifty percent reduction. The absolute change — one person in a hundred — is rarely spoken. The patient hears fifty percent and pictures a world in which they were twice as likely to die. The shield, built from numbers the patient cannot audit, is in place before the first dose.

Notice what the wall does with time. It is installed before the intervention. The patient arrives already committed to the counterfactual, and every subsequent event gets filtered through it. The shield is not a defence the patient raises under challenge. It is the prior condition of the encounter.

COVID delivered this with unprecedented coordination. The vaccine reduced severe illness by ninety-five percent.⁴ The number appeared in advertising, press conferences, pharmacy windows, social media posts. It was a relative risk reduction calculated from a trial of approximately forty thousand people in which one hundred and seventy total COVID cases occurred.⁴ The absolute reduction was roughly zero point eight percent. The ninety-five percent was mathematically real and useless to any individual patient, but it did the only thing it needed to do — it installed the counterfactual. By the time a person rolled up their sleeve, the severe illness they had been rescued from was already in their head. Every later event could only confirm it.

A patient who wants to question the shield has no tools. They cannot run the experiment on themselves. They have no access to an un-treated version of their own body. They can only trust the number, and the number was given to them by the people who sold the intervention.


4. Wall Two: Injury as Vindication

The second wall turns on when the intervention produces harm. It renames the harm, before the patient can examine it, as evidence the intervention was needed.

Chemotherapy is where this wall stands most nakedly. The treatment produces hair loss, nausea, vomiting, bone marrow suppression, secondary cancers, organ damage, cognitive decline, and in a significant fraction of patients death directly attributable to the treatment itself rather than the disease.¹ Every one of these effects is explained to the patient in advance as a sign the treatment is working. Worse side effects mean the cancer is being fought harder. The patient who is destroyed by the treatment is told, and comes to believe, that the destruction is evidence of the drug doing its job.

In any other domain, a substance that caused hair loss, marrow suppression, neuropathy and death would be called poison. In oncology, it is called treatment, and the symptoms of poisoning are called response. A patient loses her hair and is congratulated. A patient vomits for six hours and the oncologist nods with satisfaction. A patient’s white cell count collapses and the number is entered into a chart labelled progress.

The vindication continues after the treatment ends. Survivors describe the treatment as having saved them, even though the untreated survival rate for many cancers — particularly low-grade and early-stage — is substantial and, in some studies, superior.¹ Patients who do not survive are said to have succumbed to the disease. The treatment itself, in the grammar of the explanation, cannot lose. Recovery means the treatment worked. Decline means the cancer was too aggressive. Death from treatment-induced organ failure becomes death from cancer. The death certificate rarely names the chemotherapy.

The same inversion ran through the COVID rollout with identical logic. Myocarditis in a young man after the second dose was classified as mild and self-limiting, and official guidance explicitly declined to treat it as a reason to halt the programme.⁵ The injury was converted, in real time, from a reason to stop into what officials called a sign the body was responding as intended. A teenage boy who developed pericarditis was described as fortunate to have been vaccinated, because imagine how bad it would have been otherwise. The inversion operated not only in the patient but in the cardiologist giving the diagnosis, in the journalist writing the story, in the regulator reviewing the report. The injury was never an injury. It was always a sign.

Pfizer’s own documents, obtained by court order after the FDA requested seventy-five years to release them, list over one thousand two hundred distinct adverse events in the first twelve weeks of the rollout.⁶ The company had to hire more than two thousand additional staff to manage the caseload. Of two hundred and seventy pregnant women who reported injury, only thirty-two were followed up, and twenty-eight of their babies died — an eighty-seven point five percent fetal death rate in the followed cohort.⁶ These numbers were not volunteered by Pfizer. They were extracted through litigation. In the public conversation of 2021 and 2022, the events they describe were either denied or converted into evidence the programme was working.

The wall holds because the patient has no independent framework from which to resist it. When the oncologist says hair loss is good, the patient has no counter-language. When the cardiologist says myocarditis is mild, the young man has no access to population data. When the physician calls the side effects signs of the body responding properly, the patient accepts it because no other account is available in the room. The injury is named by the apparatus that produced it, and the name replaces the thing.

By the time the patient might think to examine the injury on their own terms, the third wall has already closed behind them.


5. Wall Three: The Sunk Cost Bind

The third wall stands inside the patient rather than outside, which is why it is the hardest to see. From inside, it feels like the patient’s own mind.

Consider a woman who has taken a selective serotonin reuptake inhibitor for fifteen years. She began after a divorce. The initial diagnosis was depression. She was told her brain had a chemical imbalance that the medication would correct.³ Within weeks she felt a kind of emotional flattening that her doctor called the medication working. She stayed on it. Over years she noticed she could not cry at funerals, could not feel desire, could not grieve her mother’s death when it arrived. She tried twice to come off the drug. Both times the withdrawal was catastrophic — electric shocks in her head, intrusions of suicidal thought, panic that kept her awake for days — and both times she went back on, convinced by the severity of the symptoms that she needed it.

Ask this woman whether the medication saved her and she will say yes. She will say it without hesitation and without calculation. She will also say she does not know who she was before it, because the person who took the first pill is no longer available for comparison. Fifteen years of her life have been built around the diagnosis and the drug. Her identity contains the diagnosis. Her marriage, her friendships, her children’s memories of their mother all include the medication as a feature of her personality.

To admit the medication was not needed — that her grief had been grief, that the withdrawal was the drug rather than the return of her underlying condition, that the emotional flattening was damage rather than improvement — would require her to accept that fifteen years of her life were spent inside a false frame. She would have to grieve what the medication took from her. She would have to face her absence from her children, her distance in her marriage, her unfelt goodbye to her mother. The cost of that reckoning is more than most people can pay. So she stays on the drug and says it saved her life. The gratitude is real because the cost of it being otherwise is unbearable.

Wall Three most resembles ordinary human psychology, which is why it reads as personal rather than architectural. Everyone has known some version of it — the defence of a choice after it has gone wrong, memory quietly rewriting itself to fit where money and years have already been spent. What makes the medical version structural is the scale of what has been paid in and the absence of any exit that does not require grieving it.

A man who has taken statins for twenty years, and who has watched his strength fade, his memory slip and his diabetes arrive — the exact trio the drug is known to cause² — is asked whether the statins helped. He says yes. He has to say yes. Saying no would mean accepting that two decades of growing weakness were caused by the drug he took to protect himself. It would mean admitting the heart attack he was preventing may never have been coming, that the cholesterol number he was taught to fear was a fabricated risk marker, that the man he became — slower, forgetful, diabetic — is a product of a prescription rather than of ageing. The alternative is gratitude, and he is grateful.

A mother whose child regressed after the MMR vaccination is asked whether she regrets it. Most of the time she says no. She says the vaccine was necessary. She says the autism was coming anyway. Admitting otherwise would mean accepting that she brought her child to be injured, held him down while the injection was delivered, paid for it and thanked the paediatrician afterwards. The grief on the other side of that admission is more than most parents can carry, and the wall is shaped precisely so she does not have to carry it. She can stay grateful. Her paediatrician will reinforce the gratitude. Her friends will reinforce it. The media will reinforce it. Wall Four will hold her there.

Wall Three has a property worth naming directly. It thickens with time. The longer the patient has been inside the frame, the higher the cost of leaving it becomes, and so the more fervent the defence. This is why the elderly chemotherapy survivor speaks with more heat about the drug that saved her than the recent survivor does. This is why the twenty-year statin patient is more certain of the drug’s necessity than the one-year patient. The wall grows. At some point it becomes unbreachable by any means available to the patient alone.

What completes the bind is that the captured person becomes a recruiter. The grateful SSRI patient urges her grieving friend to see a psychiatrist. The grateful chemotherapy survivor tells the newly diagnosed to accept the protocol. The grateful vaccinated parent shames the unvaccinated one at the school gate. Each captured person, defending their own wall, helps build walls around others — because their own wall depends on the walls around others holding. If the friend refuses medication and flourishes, fifteen years come into question. So the friend must be pressured, shamed, or cut off. The sunk cost in one person becomes the tribal pressure on the next, which brings the architecture to its final closure.


6. Wall Four: The Tribal Seal

The fourth wall operates outside the patient, in the community. It is the social enforcement of the narrative the patient has begun to perform, and it closes the last available exit.

Throughout 2021 this wall stood in open view. Taking the COVID vaccine was an act of public membership — selfies from vaccination centres, profile frame overlays, stickers worn on lapels, doses announced on social media. Refusing was public defection. The refusers lost jobs. They were barred from restaurants, gyms, concert venues, churches, universities, sometimes from hospitals even as visitors. They were removed from family gatherings. They were called murderers on national television by the president of France, by the prime minister of Canada, by physicians on major networks. Official communications described them as a selfish minority whose refusal was costing the compliant their freedom.

Inside that environment, an injured person who testified honestly about their injury was not merely raising a medical concern. They were defecting. Their testimony confirmed what the refusers had been saying. Their testimony was a gift to the outgroup. The tribe could not absorb it, because tribal cohesion depended on the intervention being unquestionable. So the injured were managed. Sometimes through silence — their accounts went unpublished, their videos removed, their doctors declining to code the injury as vaccine-related. Sometimes through reframing — the injury classified as COVID, as long COVID, as coincidence, as pre-existing. Sometimes through direct punishment — the injured person who insisted on naming the cause was accused of spreading misinformation, of harming public health, of serving the outgroup.

Every injured person watched this happen to others before it happened to them, and the lesson was not subtle. Most adjusted. They stopped describing their injury as an injury. They began describing it as unfortunate but acceptable. They began saying the words that returned their membership: I’m glad I took it. It could have been worse. The gratitude was not only psychologically needed. It was socially required.

Wall Four is not specific to COVID. It has stood around childhood vaccination for decades.⁷ A parent who questions the schedule loses access to paediatric practices that refuse unvaccinated patients. She is asked to leave mothers’ groups. Family members cut her off on the grounds that her choice endangers their vaccinated grandchildren. Her children are barred from schools. Any paediatrician willing to accommodate her operates under constant professional threat. Entire parenting communities organise around the vaccination question, and the penalty for dissent is exile. Parents whose children regress after vaccination, and who begin to suspect a causal link, face a choice between silence and exile. Most choose silence. Many perform gratitude instead, because gratitude reopens the community. The mother who says I’m so glad we vaccinated; his regression was just coincidence keeps her paediatrician, her friends, her family. The mother who says I believe the vaccine injured my child loses all of them.

The same seal stands around psychiatric medication, around cancer treatment, around mainstream obstetric care. In each, the patient who voices doubt is pressured first by the clinician, then by the family, then by the wider community that has already accepted the intervention as standard. Doubt is not only intellectually costly. It is socially costly, and the social cost arrives first. By the time the patient has finished working through their own doubts, the tribal apparatus is already at work on them, and the route back into membership requires the precise language of the first two walls. I’m so glad I took it.

What makes Wall Four the final seal is that it closes the one exit the other walls do not reach — the exit through honest testimony to another person. An intellectually awakened patient, who has seen through the counterfactual shield, recognised the injury as injury and refused to let sunk cost rewrite their history, still cannot speak, because speaking costs their community. The wall holds them silent. And in silence, the other three walls rebuild. The shield recloses. The injury reverts to vindication. The sunk cost reasserts its grip. The captive, left alone with the structure, returns to gratitude — because gratitude is the one posture that lets them remain intact on every side at once.


7. The Architects

The walls do not grow. They are built, funded, and maintained by identifiable actors working in documented financial arrangements. Nothing here is hidden. Everything is filed, recorded, disclosed in annual reports, visible in congressional testimony, available by Freedom of Information request. The architects have names and budgets.

Wall One — Who Builds the Counterfactual Shield

The shield is built from clinical trials and the statistical practices that translate trial results into claims patients can repeat to themselves. Most clinical trials are now run by for-profit Contract Research Organisations in jurisdictions with minimal oversight.⁸ Forty percent of medical journal articles are ghostwritten by the pharmaceutical industry.⁸ Authors with industry conflicts of interest are twenty times less likely to publish negative findings.⁸ Richard Horton, editor of The Lancet, has written that perhaps half the scientific literature is simply untrue.⁸ Marcia Angell, former editor of the New England Journal of Medicine, has written that the profession has been bought.⁸

The statistical habit that builds the counterfactual — relative risk reduction as the default metric — is a choice, not a necessity. Absolute risk reduction tells the patient what actually changes for them. Relative risk reduction amplifies the apparent effect. Every major drug marketing campaign of the last forty years has preferred the relative figure. The FDA permits it. Journals publish it. Physicians pass it along to patients who cannot tell the two apart.

For COVID, the ninety-five percent figure came from a trial of roughly forty thousand participants that recorded a total of one hundred and seventy COVID cases — one hundred and sixty-two in the placebo arm, eight in the vaccinated arm.⁴ The trial was not designed to measure transmission, hospitalisation, or death.⁴ Pfizer’s own documents show the company knew the lipid nanoparticles crossed the blood-brain and blood-testicular barriers, accumulated in ovaries and testes, and had caused reproductive harm in earlier nanoparticle studies — and proceeded without reproductive toxicity studies, citing urgency.⁶ The shield that reached hundreds of millions of minds was built from this data, presented in relative terms, and installed before the first injection.

Wall Two — Who Converts Injury Into Vindication

The apparatus that turns harm into proof operates across three layers: pharmacovigilance, physician training, and media framing.

Pharmacovigilance is structurally designed to undercount. The U.S. Vaccine Adverse Event Reporting System is passive; physicians are not required to file, and most do not. A Harvard Pilgrim Health Care study, funded by the federal government, concluded that fewer than one percent of vaccine adverse events are reported.⁹ If that figure is correct, official vaccine injury numbers understate real injury by a factor of one hundred. The study was delivered to the CDC, which declined to act on it and declined to implement active surveillance. The undercount is the default.

Physician training teaches doctors to name injuries in ways that protect the intervention. Hair loss is treatment response. Myocarditis is mild and self-limiting. Autism is coincidental regression that would have happened anyway. Death during treatment is disease progression. Medical school curricula are funded, in part, by the pharmaceutical industry.¹⁰ Two-thirds of medical school department chairs have financial ties to pharmaceutical companies.⁸ Continuing medical education — the system through which practising doctors update their knowledge — is dominated by industry-funded programmes. The doctors performing the reframing are not reading from a cynical script. They have been trained to see what they say they see.

Media framing completes the conversion. Pharmaceutical companies are the largest advertiser on American evening news.¹⁰ Twenty-seven billion dollars flows annually into pharmaceutical marketing — more than the entire NIH budget.⁸ The major news divisions are owned by investment firms — BlackRock, Vanguard — that also hold substantial stakes in pharmaceutical companies. When a young man develops myocarditis after a COVID shot and his story reaches the local news, the frame — rare, mild, unrelated to vaccination, which remains safe and effective — is not written in the newsroom. It arrives through press releases, expert contacts, and editorial relationships supplied by the same apparatus that sold the intervention.

Wall Three — Who Reinforces the Sunk Cost

The sunk cost bind is thickened by patient advocacy groups and chronic disease management organisations, most of which are funded, directly or indirectly, by the pharmaceutical industry. Depression advocacy organisations receive substantial funding from SSRI manufacturers. Cancer advocacy organisations receive funding from chemotherapy manufacturers. The official vaccine safety organisations — not the dissident ones — receive funding from vaccine manufacturers, or from the CDC, which is itself funded in part by industry through its foundation.⁸

These organisations produce the narratives that keep the bind in place. The chemotherapy survivor community is built around the claim that the treatment saved them; dissenting voices are marginalised. The depression survivor community is built around the claim that medication saved them; those who question the diagnosis or the drug are accused of encouraging suicide. The vaccinated parent community is built around the claim that vaccines are necessary; parents who describe injury are labelled anti-vaccine and removed. In each case, the community functions as a structure that reinforces the patient’s need to stay grateful.

Chronic disease management delivers the reinforcement annually. The decade-long statin patient is told, at every physical, that her cholesterol is still elevated and she should continue the drug. The SSRI patient who describes emotional flatness is told the dose may need adjusting. A patient reporting withdrawal symptoms is told she is experiencing the return of her underlying condition. The clinical encounter reinforces the sunk cost every time she walks in. Her doubts, if she has any, are resolved by the clinician in favour of continued treatment.

Wall Four — Who Builds the Tribal Seal

The seal is built through public health communication, employer mandates, regulatory policy, media coordination, and the enforcement infrastructure of digital platforms.

COVID-era public health communication was produced and coordinated across federal agencies, corporate media, social media companies, and advertising campaigns. The specific framing — that the unvaccinated endangered the vaccinated, that refusal was antisocial, that vaccination was a civic duty — was not organic. It was produced. The Biden administration funded a multi-hundred-million-dollar campaign to promote vaccination.¹¹ Equivalent campaigns ran in every Western country. The narrative was coordinated enough that the same talking points surfaced nearly simultaneously across English-language media in multiple nations.

Employer mandates provided the enforcement. Workers were required to accept the injection as a condition of employment. Refusers were dismissed, often for cause, stripped of unemployment benefits and professional licences. Healthcare workers, teachers, service members, and federal contractors faced mandates that ended careers built over decades. The mandates did not issue from a vacuum. They were produced by regulatory decisions, legal memoranda, and executive orders that made refusal economically catastrophic.

Platform moderation finished the seal. Social media companies, under pressure from federal officials, removed accounts, posts and videos describing vaccine injury.¹¹ The label misinformation was applied to accurate first-person accounts. Fact-checking systems, funded in part by industry-adjacent foundations, rated injury reports false. The injured could not speak publicly about their own injury without suppression. In the digital age, the fourth wall was algorithmic.

Opioids: The Paradigm Run to Completion

The four walls can be seen at their fullest — and their eventual failure — in the OxyContin case, because that one ran all the way to the end.

Purdue Pharma received FDA approval for OxyContin in 1995. The approval process included language, permitted by the FDA, describing the drug as less addictive than other opioids because of its delayed-release formulation. The language was not supported by evidence. It was promotional text permitted into the regulatory record.¹² The company built a sales force that trained physicians to prescribe OxyContin for chronic pain, funded pseudo-science suggesting that patients seeking more of the drug were suffering from pseudo-addiction to be treated with higher doses, and paid consultants and patient advocacy groups to reinforce the claim that OxyContin was safe.¹²

The counterfactual shield was installed: patients were taught that without adequate pain management they would suffer unnecessarily. Wall Two took over when harm arrived: patients who developed tolerance and needed higher doses were told they had pseudo-addiction and required more of the drug, not less. Wall Three tightened as the months passed: patients who had been on OxyContin for years had organised their lives around it and could not stop without devastating withdrawal, and the withdrawal was interpreted as proof they had needed the drug all along. Wall Four held: patients who became dependent were categorised as addicts — a moral failing, a personal weakness — a category that separated them from each other and from the community that might otherwise have listened to them.

Patients thanked the physicians who prescribed it. They gave interviews thanking Purdue. Many became dependent and many of them died, and among those who died some were still grateful at the end. Then the bodies became too many to hide. Hundreds of thousands of deaths, families documenting the progression from legitimate prescription to heroin to fentanyl, internal Purdue documents forced into the open through litigation, Sackler family settlements, DEA investigations and congressional hearings. The walls came down twenty years late, with bodies stacked against them.

The lesson of OxyContin is not that the system corrects itself. The system corrects only when the damage becomes too visible to contain, and by then most of the damage is already done. Everything known at the end was knowable at the beginning. The FDA had the data. Purdue had its internal memoranda. The paid consultants had the complaints. The patients did not know, because the four walls stood around them, and most of them died grateful.


8. What the Captured Person Is Owed

If the architecture is engineered, the captured person is not a fool. They were not gullible or poorly educated. They were inside a structure built by specific actors for specific reasons, and its purpose was to produce exactly the response they gave — gratitude from the injured, defence from the captured, compliance from the well.

This is the first thing they are owed: the return of their dignity. The woman in the hospital bed who thanked the vaccine that stroked her is not a fool. She is inside the room, and her gratitude is the designed output of a designed apparatus. The same goes for the chemotherapy survivor who credits the poisoning, the parent who defends the schedule, the grandfather on his twentieth year of statins, the widow who still has OxyContin in the cupboard. None of them failed. A structure was built around them. The structure is what failed, because it was never designed to succeed at healing. It was designed to succeed at extraction, and at that it succeeded brilliantly.

The second thing they are owed is clarity about what their gratitude costs. When the injured cannot testify honestly about their injury, the injury does not appear in the record. It never becomes a safety signal, never gets studied, never reaches the next person considering the same intervention. The apparatus that produced the injury continues to produce it. The signals that might have shut down OxyContin in 1997 rather than 2017 were there in 1997, in the voices of the first dependent patients. Those voices were absorbed into the gratitude of the captured and converted into testimonials. The delay cost hundreds of thousands of lives.

The captured person’s dissenting voice is the most valuable instrument in medicine. Grateful testimony has been manufactured at scale for a century — that is what the previous sections have shown. What cannot be manufactured is the captured person turning, after years of defending the injury, and naming it. Once one captured person speaks that way, others recognise themselves in the testimony, and the walls begin to fail at the only point where they can fail — in the social layer, from inside the community. The injured testifying to the injured breaks the tribal seal. The tribal seal failing exposes the sunk cost. The sunk cost examined reveals the injury as injury rather than as vindication. The injury named dissolves the shield. The walls depend on each other, and the one that gives first is the fourth, because the fourth is the only one where another person’s voice can reach.

This is why the essay closes here, and not with a call to action. There is nothing general to be done. There is only the specific, costly, socially expensive act of breaking the silence — by the captured person who survives long enough to recant their gratitude, or, where the captured cannot speak, by those close enough to them to testify on their behalf. That single act, repeated, is the entire dismantling. It is what the apparatus was never designed to process, and it is the only thing that has ever worked against it. The OxyContin walls came down because the families of the dead spoke for those who could no longer speak. The Vioxx walls came down because injured patients outlived the cover-up long enough to name it. The DES walls came down because the daughters, injured in utero by what their mothers had been given, lived to testify to the inheritance. The machine ran, in each case, until the testimony arrived from someone it could not silence. Then it stopped.

The captured person speaking honestly is not an act of politics or rebellion. It is accurate description. What was done to the body was real, the captivity that followed was real, and the people who built it can be named. Under the gratitude is a person who has the right to say, at last, what actually happened.

That voice is what the room was built to prevent. It is also the only thing that has ever brought a room like this down.


References

  1. Thomas Cowan, discussed in When Your Body Whispers, Listen: The Intelligence of SymptomsNew England Journal of Medicine finding on breast cancer overdiagnosis: approximately 1.3 million American women overdiagnosed over thirty years. On lead-time bias and survival statistic manipulation in early-stage cancer screening, see H. Gilbert Welch and colleagues’ work on overdiagnosis.
  2. John Abramson, MD, Harvard Medical School; Peter Gøtzsche, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare (CRC Press, 2017). On the chronic disease cascade around statins — muscle pain, memory effects, diabetes — see Extraction: The Middle Class as Colony.
  3. Andrew Kaufman, MD, on SSRI mortality and pediatric prescribing pressures; Peter Breggin’s work on the suicide signal eventually acknowledged in black box warnings. On identity capture around psychiatric diagnosis, see Four Causes, Seventy Thousand Diseases.
  4. Pfizer BNT162b2 Phase 3 trial data as summarised in the Pfizer Document Analysis Report (War Room/DailyClout, December 2022). The 95% relative risk reduction figure was calculated from 170 total COVID cases in a trial of approximately 40,000 participants.
  5. CDC and FDA advisory communications on post-vaccination myocarditis, 2021–2022, including the June 2021 ACIP meeting that concluded benefits outweighed risks for adolescents and young adults. Critical account: Peter McCullough, MD, and Nicolas Hulscher’s published work on vaccine-associated myocarditis.
  6. Pfizer Document Analysis Report, War Room/DailyClout (December 2022), summarising the FDA-released Pfizer clinical trial documents obtained through court order after the FDA requested 75 years to release them.
  7. Turtles All the Way Down: Vaccine Science and Myth (2019). The 2013 Institute of Medicine report acknowledged that the childhood vaccination schedule as a whole has not been properly studied for safety.
  8. Peter Gøtzsche, Deadly Medicines and Organised Crime (2017); Marcia Angell, The Truth About the Drug Companies; Richard Horton, The Lancet, 2015. Aggregated in Extraction: The Middle Class as Colony.
  9. Lazarus R et al., “Electronic Support for Public Health–Vaccines Adverse Event Reporting System (ESP:VAERS),” Harvard Pilgrim Health Care, funded by AHRQ, 2010. Finding: fewer than 1% of vaccine adverse events are reported.
  10. Abramson J and Starfield B on the purpose of commercially funded clinical research. FDA revolving door: nine of the last ten FDA commissioners as of 2019 joined pharmaceutical companies after leaving the agency. Congressional capture: more than two-thirds of Congress took money from the pharmaceutical industry in 2020.
  11. Missouri v. Biden (2023) and related federal court findings on federal coordination with social media platforms to suppress COVID-related speech, including first-person vaccine injury accounts. Twitter Files disclosures, December 2022 – March 2023.
  12. Patrick Radden Keefe, Empire of Pain: The Secret History of the Sackler Dynasty (2021); Barry Meier, Pain Killer: An Empire of Deceit and the Origin of America’s Opioid Epidemic (updated edition, 2018); internal Purdue Pharma documents released through multi-state litigation and the 2020 Department of Justice settlement.

April 18, 2026 Posted by | Deception, Full Spectrum Dominance, Science and Pseudo-Science, Timeless or most popular | , , , , | Comments Off on The Gratitude of the Captured

Fact-Checking the “Placebo Control” Fact Checkers

By Aaron Siri | Injecting Freedom | April 13, 2026

The fact is, not a single routine injected childhood vaccine on the CDC schedule was licensed based on a placebo-controlled trial, nor was any vaccine used as a control to license any such vaccine.

I was recently sent the following two links which claim that placebo-control groups were used to license routine childhood vaccines:

If you read these two articles, you will notice they contain no actual evidence and no link to any clinical trial. That is because the reality is that not a single routine injected childhood vaccine on the CDC schedule was licensed based on a placebo-controlled trial. Nor, when another vaccine was used as the control, was that vaccine licensed based on a placebo-controlled trial. And so on and so forth down the chain.

Unlike these two nonsense articles, which claim to be “fact checks,” below are the actual facts with the actual evidence from the FDA showing exactly what the control was when licensing each routine childhood vaccine. (You can also read a more fulsome, fun, narrated version of this list in Chapter 10 of Vaccines, Amen.)

One last thing, as for the definition of what is a “placebo,” per the FDA, in its guidance regarding placebo-controlled trials: “Placebos, defined as inert substances with no pharmacologic activity.” Also see this FDA source: “placebo control … group that receives an inert treatment…” And per the CDC, “A substance or treatment that has no effect on living beings.” With that, here is the list:

  • HepB vaccine (Birth 1M 6M)
    • Recombivax HB (Merck) licensed for babies based on trials with no placebo control & 5 days of safety monitoring after injection. See Package insert § 6.1.
    • Engerix B (GSK) licensed for babies based on trials with no placebo control & 4 days of safety monitoring after injection. See Package insert § 6.1.
  • DTaP vaccine (2M 4M 6M 15M 4Y)
    • Infanrix (GSK) licensed for babies based on trials with no placebo control (DTP vaccine used as a control) & up to 30 days of safety review after injection. See Package insert § 6.1. (Note that DTP was not licensed in a placebo-controlled trial and increases mortality.)
    • Daptacel (Sanofi) licensed for babies based on trials with no placebo control (DT or DTP vaccine used as control) & 2 months of safety review after injection except one trial which was 6 months with no control, 1,454 children, and “[w]ithin 30 days following any dose of DAPTACEL, 3.9% subjects reported at least one serious adverse event.” See Package insert § 6.1. (See note regarding DTP under Infanrix, above.)
  • PCV vaccine (2M 4M 6M 12M)
    • Prevnar 13, PCV-13 (Wyeth, part of Pfizer) licensed for babies based on trials with no placebo control (Prevnar 7 used as a control, and Prevnar 7 was licensed based on trial in which the control was another experimental vaccine) & 6 months of safety review after injection which found, “Serious adverse events reported following vaccination in infants and toddlers occurred in 8.2% among Prevnar 13 recipients and 7.2% among Prevnar 7 recipients.” See Package insert § 6.1. (Note the package insert for Prevnar 7 states the control in its licensing trial was an “Investigational meningococcal group C conjugate vaccine.”)
    • Vaxneuvance PCV-15 (Merck) licensed for babies based on trials with no placebo control (Prevnar 13 used as the control) & up to 6 months of safety review after injection, finding that, “Among children who received VAXNEUVANCE (N=3,349) or Prevnar 13 (N=1,814) … serious adverse events up to 6 months following vaccination with the 4-dose series were reported by 9.6% of VAXNEUVANCE recipients and by 8.9% of Prevnar 13 recipients.” Deemed “safe” because, “[t]here were no notable patterns or numerical imbalances between vaccination groups.” See Package insert § 6.1.
    • Prevnar 20, PCV-20 (Pfizer) licensed for babies based on trials with no placebo control (Prevnar 13 was used as the control) & up to 6 months of safety review after injection that again showed high rates of serious events (this time broken up into two categories – “serious adverse events (SAEs)” and “newly diagnosed chronic medical conditions (NDCMCs)”) in both vaccine groups but deemed “safe” because “no notable patterns or imbalances between vaccine groups.” See Package insert § 6.1; Clinical Review.
  • Polio vaccine (2M 4M 6M 4Y)
    • IPOL (Sanofi) licensed in 1990 for babies based on trials with no placebo control & 3 days of safety review after injection. Sanofi reports that, “Although no causal relationship has been established, deaths have occurred in temporal association after vaccination of infants with IPV.” See Package insert at 14-17. (Note that IPOL is an injected polio vaccine and is the only polio vaccine used in the U.S. for over two decades. It is a very different product than the polio vaccine developed by Salk in the 1950s—and, as noted above, ceased being used in the U.S. in the 1960s—and hence the trials of Salk’s vaccine from the early 1950s were not relied upon to license IPOL.)
  • Hib vaccine (2M 4M 6M 12M)
    • ActHIB (Sanofi) licensed for babies based on trials with no placebo control (Hepatitis B vaccine used as control) & 30 days of safety review after injection during which 3.4% experienced a serious adverse event but “[n]one was assessed by the investigators [Sanofi] as related to the study of vaccines.” See Package insert § 6.1; Basis of Approval at 8.
    • Hiberix (GSK) licensed for babies based on trials with no placebo control (ActHIB used as the control) & 31 days of safety review after injection. See Package insert § 6.1; Clinical review at 20-21.
    • Liquid PedvaxHIB (Merck) licensed for babies based on trials with no placebo control (Lyophilized PedvaxHIB used a control) & 3 days of safety review after injection. See Package insert at 6-8. (Note that Lyophilized PedvaxHIB was tested in a trial in which controls were given lactose, aluminum adjuvant, and thimerosal and there is no indication Lyophilized PedvaxHIB was ever licensed.)
  • Rotavirus vaccine (2M 4M 6M) (Note that every vaccine on the CDC childhood schedule is given via injection, except for one flu vaccine given by nasal spray and the rotavirus vaccines, which are given by oral drops .)
    • Rotarix (GSK) licensed for babies based on trials without a placebo control (the control group received an oral drop that included Dextran, Sorbitol, Amino Acids, Dulbecco’s Modified Eagle Medium, and Xanthan) & 31 days of safety review after oral dose and up to a year in some trials for cases of intussusception. There were more deaths in the group receiving Rotarix than the purported placebo. As disclosed by the FDA and GSK: “During the entire course of 8 clinical studies (Studies 1 to 8), there were 68 (0.19%) deaths following administration of ROTARIX (n = 36,755) and 50 (0.15%) deaths following placebo administration (n = 34,454). The most commonly reported cause of death following vaccination was pneumonia, which was observed in 19 (0.05%) recipients of ROTARIX and 10 (0.03%) placebo recipients (RR: 1.74, 95% CI: 0.76, 4.23).” See Package insert § 6.1 (claims used a placebo); Clinical review at 23-24 (admits the purported “placebo” included all the foregoing ingredients).
    • RotaTeq (Merck) licensed for babies based on trials without a placebo control (the control group received an oral drop that included Polysorbate-80, Tissue Culture Medium, Fetal Bovine Serum, and Sodium Phosphate) & 42 days of safety review after each oral dose and up to a year for cases of intussusception. See Package insert § 6.1 (claims used placebo); Clinical reports at 445 etc. (admits the purported “placebo” included all the foregoing ingredients).
  • Covid-19 vaccine (6M 8M and then Annually)
    • Comirnaty (Pfizer) authorized for emergency use in babies based on trial with a placebo control (finally!) & 6 months of safety review after injection. See Package insert § 6.1. (Note that Pfizer’s EUA was revoked and it is not currently licensed for children under age 5.) Also, while Comirnaty’s trial had a placebo control group, that group was unblinded and most were vaccinated during the 6-month safety review period. The 16- and 17-year-old data is not separated from the adult data, but the 12- to 15-year-old data is separated and included only 1,131 children who received a vaccine, and the case of one participant reflects how this trial was conducted.)
    • Spikevax (Moderna) authorized for emergency use in babies based on trial with placebo control. Depending on the age group, the median duration of blinded safety follow-up was 51 to 71 days. Placebo controls were unblinded and mostly vaccinated during the trial. See Package insert at § 6.1; FDA Briefing at 10.
  • Flu vaccine (6M 7M and then Annually)
    • The formulation for each influenza vaccine changes annually and there is no clinical trial carried out for each new formulation. (In any event, none of the clinical trials for the original formulation of any injected influenza vaccine for children had a placebo control group, see letter pp.13-14, even though some adult trials did, showing it could have been done. See FDA documentation and compare child and adult portions of Section 6.1 of each flu vaccine package insert. The one inhaled influenza vaccine’s original trial had a placebo but, again, its formulation changes every year and is not safety tested in any trial.)
  • MMR vaccine (12M 4Y)
    • M-M-R-II (Merck) licensed based on a trial with no placebo control & 42 days of safety review after injection in a trial with a total of only 834 children of which a third developed gastrointestinal issues and a third respiratory issues. See Clinical reports. (This patently deficient, underpowered, unblinded, and non-randomized trial is unsurprisingly not even listed in the safety section of M-M-R-II’s package insert. Also note that the original MMR’s clinical trial was similarly deficient and also showed a high and concerning rate of gastrointestinal, respiratory and other issues, as compared to the small untreated control group—see pages 12 and 13. In any event, the original MMR was a different product that did not include millions of pieces of human DNA and cellular debris, as does M-M-R-II, which is likely why it was not used as a control in the trial for M-M-R-II).
    • Priorix (GSK) licensed based on trials with no placebo control (M-M-R-II used as the control) & 6 months of safety review after injection in which both vaccine groups had a high rate of serious adverse events, emergency room visits, and new onset of chronic diseases (e.g., autoimmune disorders, asthma, type I diabetes, vasculitis, celiac disease, thrombocytopenia, and allergies). See Package insert § 6.1; Sup materials at 12.
  • Varicella (chicken pox) vaccine (12M 4Y)
    • Varivax (Merck) licensed based on trials with no placebo control & 70 days of safety review after injection. In the one controlled trial of 956 children, around half received Varivax and half received the “placebo” injection of 45 mg of neomycin per milliliter. There was one trial in which 32 children received Varivax and 29 children received nothing and then received Varivax eight weeks later; during this eight-week period, the Varivax group had double the rate of ear infection and a 50% increase in respiratory infection. As for serious adverse events, Merck did not consider any related to Varivax. See Package insert § 6.1; Merck study at 2; Clinical reports.
  • HepA vaccine (12M 18M)
    • Havrix (GSK) licensed based on trials with no placebo control (Engerix-B was used as a control) & 31 days of safety review after injection with a phone call follow-up at 6 months. See Package insert § 6.1.
    • Vaqta (Merck) licensed based on trials with no placebo control (an injection of AAHS, an aluminum adjuvant, and thimerosal, a form of mercury, were used as a control) & up to 42 days of safety review after injection. See Package insert § 6.1 (using term “placebo”); Merck study at 454 (admits the purported “placebo” included all the foregoing ingredients). (Note that trials for Havrix and Vaqta occurred at roughly the same time and, because there was no licensed Hepatitis A vaccine at that time, there was no excuse for not using a placebo control in these trials. It is also startling that Engerix-B, which had 4 days of safety monitoring in its trial, was used as the control for Havrix, and that an injection of known cyto-and-neuro toxic substances, AAHS and thimerosal, were used as a control for Vaqta instead of just a saline injection.)
  • Tdap vaccine (11Y)
    • Adacel (Sanofi) licensed based on trials with no placebo control (Td, for adult use, was used as a control) & up to 6 months of safety review after injection. See Package insert § 6.1.
    • Boostrix (GSK) licensed based on trials with no placebo control (DECAVAC or Adacel was used as a control) & up to 6 months of safety review after injection. See Package insert § 6.1.
  • HPV vaccine (9Y 9 ½Y)
    • Gardasil 9 (Merck) was licensed based on trials in which safety was reviewed after injection for 1 month in five of the clinical trials, 6 months in a lot consistency trial, and 4 years in one trial of women aged 16 to 26 years (reflecting that a safety trial of a more appropriate duration is possible). These Gardasil 9 trials were either not controlled or used Gardasil 4 as the control, except for one trial in which 306 participants received a placebo but only after receiving the full series of Gardasil 4 injections. See Clinical review at 17-19. (Note that in Gardasil 4’s clinical trial, controls received an aluminum adjuvant, AAHS, except 320 people labeled “Saline Placebo” that actually received all vaccine ingredients except antigens and AAHS. Also, across all these trials, 2-3% of participants receiving vaccine or aluminum adjuvant—used to induce autoimmunity—had a suspected autoimmune disorder.)
  • MenACYW vaccine (11Y 16Y)
    • Menactra (Sanofi) licensed based on trials with no placebo control (Menomune used as the control, and amazingly the safety section of the package insert for Menomune lists this same trial in which it is being used as a control) & up to 6 months of safety review after injection. See Package insert § 6.1.
    • Menveo (GSK) licensed based on trials with no placebo control (Menactra, Boostrix, or other vaccines used as a control) & up to 6 months of safety review after injection. See Package insert § 6.1.
    • MenQuadfi (Sanofi) licensed based on trials with no placebo control (Menveo or other vaccines used as a control) & up to 6 months of safety review after injection. See Package insert § 6.1. (The three Men4 vaccines provide another good example of the vaccine safety pyramid scheme because Menomune was licensed without a placebo-controlled trial and then used as the control to license Menactra; Menactra is then used as the control to license Menveo; and then Menveo is used as the control to license MenQuadfi. The actual safety profile, putting aside the limited 6-month safety period, is unknown since Menomune’s safety baseline was never established in a placebo-controlled trial.)
  • NON-ROUTINE VACCINE: MenB vaccine (16Y 16 ½Y + if indicated)
    • Bexsero (GSK) licensed based on trials with no placebo control group (either uncontrolled or control group was given an injection of aluminum hydroxide and, in one trial involving 120 adolescents, a saline injection followed by an injection of Menveo and hence FDA labels this an “active control” and not a “placebo control” trial) & 30 days of safety review after injection. See Summary basis at 14-15; Clinical review at 40.
    • Trumenba (Pfizer) licensed based on trials with no placebo control group other than 12 people in a dose ranging phase II study (otherwise the controls were injection of Gardasil+placebo, dTaP-IPV+placebo, HepA+placebo, or Menactra+Adacel+placebo) & 30 days of safety review after injection for one of the three trials and up to 11 months in the other two trials. See Summary basis at 4; Clinical review at 9-10.
  • NON-ROUTINE VACCINE: PPSV23 vaccine (2Y+ if indicated)
    • Pneumovax 23 (Merck) is licensed for children 2 years and older but there is no indication that there was any clinical trial involving anyone younger than 16 years of age that the FDA relied upon to license this vaccine. See FDA documentation.
  • NON-ROUTINE VACCINE: Dengue vaccine (6Y+ if previously had dengue and live in area dengue is endemic)
    • Dengvaxia (Sanofi) licensed based on a trial with 11,474 children receiving a placebo control (saline injection) & 5 years of safety review after injection. Meaning, the 17th and last vaccine on the CDC’s childhood vaccine schedule, is apparently the first vaccine that underwent a longer-term placebo-controlled trial prior to licensure! This trial stands as the proof that a longer-term placebo-controlled trial of a childhood vaccine is possible! See Statistical review at 10; Package insert at 4. (Note for this vaccine, it was learned that children under 6 years old had an increased risk of severe harm and death from this vaccine—harm that would likely never have been uncovered by the trials performed for any of the other 16 vaccines. It was also found that children older than 6 who had never had dengue and received this vaccine likewise had a seriously increased risk of severe harm and death. Hence, this vaccine is only to be given to older children who have previously had dengue. As disclosed by the FDA and Sanofi: “Those not previously infected are at increased risk for severe dengue disease when vaccinated and subsequently infected with dengue virus.” This vaccine is only recommended for children in endemic dengue areas and dengue is not endemic in the United States.)

April 16, 2026 Posted by | Deception, Timeless or most popular | | Comments Off on Fact-Checking the “Placebo Control” Fact Checkers

Feeling Better, Getting Worse: How Psychiatric Drugs Create the Illusion They Cure

An Essay on Short-Term Improvement, Long-Term Dependence, and the Evidence Patients Never See

Lies are Unbekoming | April 9, 2026

Of 18,426 patients enrolled in 71 antidepressant trials — 67,319 pages of clinical data, a stack seven metres high, obtained from drug regulators and read for the first time by Peter Gøtzsche’s research group — 12 percent more dropped out while taking the drug than while taking placebo.¹

The psychiatrists’ position is that these drugs do more good than harm. The patients, through their behaviour, delivered the opposite verdict. They preferred the sugar pill.

Nobody who takes a psychiatric drug and reports feeling better is lying. The experience is real. But what produced it, what it is made of, and what it costs — none of this is what the patient was told. Six mechanisms account for almost everything people attribute to their medication. None of them require the drug to be treating a disease.

The Prescription

A person in distress sits across from a doctor. Fifteen minutes later they leave with a diagnosis and a prescription. They are told they have a chemical imbalance that the drug will correct. They may be told depression runs in families — that there is a genetic predisposition, a biological vulnerability they inherited. They are told to give it a few weeks.

The chemical imbalance theory has been abandoned by every serious researcher in the field.² No gene or set of genes for depression has ever been identified despite decades of searching and billions in funding. As Peter Breggin observed, there is no substantial scientific evidence that depression is genetic in origin — and telling patients otherwise leaves them convinced they are stuck with an innate defect, dependent on experts, and resigned to lifelong medication.⁴⁵ The drug was approved on the basis of trials lasting five to six weeks.³ Long-term effects have never been properly studied.⁴ And the condition being treated has a spontaneous remission rate so high that the head of the NIMH’s depression section once observed that most depressive episodes “will run their course and terminate with virtually complete recovery without specific intervention.”⁵

The patient knows none of this. They go home, swallow the pill, and wait.

The First Weeks: Time Heals What the Pill Takes Credit For

Depression, before pharmacology claimed it, was understood to be self-limiting. NIMH psychopharmacologist Jonathan Cole wrote in 1964: “Depression is, on the whole, one of the psychiatric conditions with the best prognosis for eventual recovery with or without treatment. Most depressions are self-limited.”⁶ His colleague Nathan Kline: “In the treatment of depression, one always has as an ally the fact that most depressions terminate in spontaneous remissions. This means that in many cases regardless of what one does the patient eventually will begin to get better.”⁷

Cole and Kline were not dissidents. They were among the most prominent figures in American psychopharmacology.

A study tracking eighty-four patients through untreated depressive episodes found that 23 percent recovered within one month, 67 percent within six months, and 85 percent within a year.⁸ Mark Posternak, the researcher, noted that his results confirmed Kraepelin’s century-old observation that untreated depression typically clears within six to eight months. Dean Schuyler, who headed the NIMH’s depression section, recognised the problem as early as 1974: spontaneous recovery rates were so high that it was difficult to “judge the efficacy of a drug, a treatment or psychotherapy in depressed patients.”⁹

Antidepressants take four to six weeks to produce their claimed effect. Spontaneous recovery begins immediately and continues at roughly 2 percent per week.¹⁰ A person who starts a drug during a depressive episode is beginning treatment at the moment when natural recovery is already underway. A month later, they feel better. The drug gets the credit. The calendar does not.

The Side Effects That Sell the Cure

In the NIMH’s review of all antidepressant studies, well-controlled trials showed 61 percent of drug-treated patients improved versus 46 percent on placebo — a net benefit of 15 percent.¹¹ Irving Kirsch, reviewing FDA data on Prozac, Effexor, Serzone, and Paxil, found the drug-placebo difference on the Hamilton Rating Scale was 1.8 points. The UK’s National Institute for Clinical Excellence had established 3 points as the minimum for clinical significance.¹² The best Danish meta-analysis found a difference of 2 points, and the smallest effect that can actually be perceived on this scale is 5 to 6 points.¹³

That is the margin on which billions of prescriptions rest.

Breggin identified why even this margin exists. He called it the “enhanced placebo effect.” A patient on a sugar pill senses, consciously or not, that nothing powerful has entered their system. An antidepressant produces noticeable physical effects — dry mouth, nausea, drowsiness, sexual dysfunction, weight change. The patient feels these and concludes, reasonably, that they are taking potent medicine. The side effects convince the patient the drug is real. This conviction amplifies the placebo response.¹⁴

Investigators tested this in at least seven studies comparing tricyclic antidepressants to “active” placebos — chemicals that produce unpleasant side effects like dry mouth but have no antidepressant properties. In six of the seven, there was no difference in outcomes.¹⁵ When both pills cause side effects, neither is superior. A Cochrane review confirmed the finding.¹⁶

The entire marginal advantage of antidepressants over placebo may be an artefact of broken blinding. Patients and clinicians can guess who is on the drug and who is on the sugar pill, because the drug has obvious physical effects. This knowledge contaminates every rating, every assessment, every reported outcome.

The NIH-funded St. John’s wort trial demonstrated this by accident. Because St. John’s wort causes side effects similar to an antidepressant, this trial was genuinely blinded — neither patients nor clinicians could tell who was taking what. Results: 24 percent of the herbal group had a full response, 25 percent of the Zoloft group, 32 percent of the placebo group. Zoloft did not outperform placebo. The investigators concluded that the herb was ineffective and neglected to mention that their own drug had failed the same test.¹⁷

The Flattening

Psychiatric drugs produce their effects the same way in patients, healthy volunteers, and laboratory animals. Gøtzsche, drawing on clinical trial data, lists what these effects actually are: numbing of feelings, emotional blunting, drowsiness, reduced concern about oneself and others, diminished capacity for sexual function and romantic attachment.¹⁸

These are not side effects. They are the effects. The drug does not selectively remove depression while leaving everything else intact. It reduces the brain’s capacity to generate emotional intensity across the board. A person who was in anguish may interpret this flattening as recovery. A clinician observing calmer behaviour will rate the patient as improved. Both are observing something real. Neither is observing the treatment of a disease.

Breggin made the point precisely: antidepressants reduce emotional responsiveness generally, which is why they are prescribed not only for depression but for anxiety, panic attacks, obsessive-compulsive behaviour, bulimia, chronic pain, and aggression. They are not treating different diseases through different mechanisms. They are producing the same blunting effect across all of them.¹⁹

The rating scales used to measure “improvement” cooperate with this illusion. The Hamilton Depression Rating Scale — the standard instrument — scores items like sleep quality, appetite, and psychomotor behaviour. A sedated patient who sleeps more and eats more registers as improved. Breggin observed that psychiatric improvement standards are often behavioural (”sleeps better,” “gaining weight”) rather than psychological (”feels better about life,” “actively building a better future”).²⁰ A tranquillised patient and a recovered patient score identically.

Patient self-ratings tell a different story. In Greenberg and Fisher’s meta-analysis of newer antidepressants, patient self-ratings showed virtually no benefit beyond placebo.²¹ The doctors see improvement. The patients, asked directly, do not.

In Denmark, researchers surveyed patients on antidepressants. Half agreed the drugs altered their personality and that they had less control over their thoughts and feelings. The psychiatrists who received these results refused to believe what their own patients told them, called the patients ignorant, and recommended “psychoeducation.”²² The patients’ relatives, independently surveyed, agreed with the patients.

Breggin described a further mechanism operating in some patients: mild organic brain syndrome. Antidepressants, through their general toxicity, can produce a delirium characterised by memory difficulties, confusion, impaired judgment, and mood instability. A patient in this state may experience artificial euphoria or generalised apathy and be evaluated as “improved” — because depression requires a relatively intact brain to sustain itself. Damage the brain sufficiently and the depression lifts, not because the distress has been addressed, but because the capacity to experience it has been impaired.²³ A Yale study found this drug-induced delirium appeared two to four weeks after starting treatment — the exact interval when “therapeutic response” is expected — in more than one-third of patients over age forty.²⁴

The Attempt to Stop

Months pass. Perhaps years. The patient decides to stop. They feel well. They are tired of the side effects. They may have read something that unsettled them.

Within days: headaches, dizziness, nausea, insomnia, agitation, anxiety, confusion, fatigue, flu-like symptoms, electric shock sensations. As many as 50 percent of patients who stop antidepressants experience these withdrawal effects.²⁵

The symptoms vanish when the drug is restarted. The trap closes.

Patient and doctor both conclude that the return of distress proves the drug was treating a real condition. The depression has “come back.” The drug is “needed.” But the symptoms are not relapse. They are withdrawal. The brain, having adapted to the presence of a chemical that altered its neurotransmitter activity, protests the chemical’s removal.

Gøtzsche coined a term for this: “abstinence depression.” A depression that occurs in a patient who is not currently depressed but whose drug is stopped too quickly. Its hallmark: symptoms appear rapidly after discontinuation and disappear within hours when the full dose is resumed. A real depressive episode does not respond to a pill within hours. The speed of response is the diagnostic marker that separates withdrawal from genuine relapse.²⁶

He demonstrated this with a cold turkey trial. Stable, well patients were secretly switched to placebo for 5 to 8 days. Twenty-five of 122 patients on sertraline or paroxetine met criteria for depression during that window. Gøtzsche calculated the expected number of genuine relapses in such a short period, based on known relapse rates from an adolescent depression study: 0.03. Effectively zero. Every one of the twenty-five “relapses” was a withdrawal reaction.²⁷

The profession does not call these symptoms “withdrawal.” It calls them “discontinuation syndrome.” Gary Greenberg described this renaming for what it is: in any other context, a malaise that appears when you stop a drug and disappears when you restart it is called dependence with withdrawal. Calling it “discontinuation syndrome” keeps antidepressants at a comfortable distance from alcohol, benzodiazepines, and opioids.²⁸

The clinical consequences are specific. Breggin described the vicious circle: a patient attempts to stop the drug and experiences withdrawal. The treating professionals mistake withdrawal for relapse. The drug is reinstated. The patient — who might have recovered fully without the medication — is now physiologically dependent on a chemical they were told was safe to stop at any time.²⁹ A study of twenty-two children withdrawn from the tricyclic Tofranil documented this pattern: staff attributed the children’s withdrawal symptoms to “mental illness,” to stress, to allergies, even to viral illness. Antidepressants were restarted in children who were “mistakenly diagnosed as relapsing during the withdrawal period.”³⁰

Gøtzsche reviewed the five most-used psychiatry textbooks in Denmark and found that their withdrawal guidance is wrong and frequently dangerous. Doctors taper too quickly and in linear fashion rather than the exponential taper the drugs’ pharmacology demands. None of the textbooks acknowledged that withdrawal symptoms and disease symptoms are often identical.³¹

The Long Decline

European psychiatrists began noticing the pattern in the 1960s. German physician H. P. Hoheisel reported in 1966 that antidepressant exposure appeared to be “shortening the intervals” between depressive episodes. A Yugoslavian doctor observed the drugs were causing “chronification” of the disease. Bulgarian psychiatrist Nikola Schipkowensky agreed: the tricyclics were inducing “a change to a more chronic course.”³²

Dutch physician J. D. Van Scheyen examined ninety-four depressed patients over five years. Long-term antidepressant medication, he found, “exerts a paradoxical effect on the recurrent nature of the vital depression” — the drugs increased the rate of recurrence and shortened the time between episodes.³³

In 1994, Italian psychiatrist Giovanni Fava forced the question into the open. The drugs, he argued, perturb neurotransmitter systems in ways that produce compensatory brain changes. When the drug is stopped, these changes operate unopposed, producing withdrawal and increasing vulnerability to relapse. The longer someone takes the drug, the worse this becomes. Antidepressants, Fava concluded, “may propel the illness to a more malignant and treatment unresponsive course.” He raised the possibility that the drugs cause “irreversible receptor modifications” that “sensitize” the brain to depression.³⁴

Ross Baldessarini of Harvard confirmed it: half of all patients withdrawn from antidepressants relapsed within fourteen months, and the longer a person had been on the drug, the higher the relapse rate upon withdrawal.³⁵

The profession’s response was not investigation. Donald Klein of Columbia University told Psychiatric News: “The industry is not interested, the NIMH is not interested, and the FDA is not interested. Nobody is interested.”³⁶

Instead, the history was rewritten. The pre-drug studies showing that depression was episodic and self-limiting were declared “flawed.” The 1999 APA Textbook of Psychiatry stated that it was previously believed “most patients would eventually recover from a major depressive episode. However, more extensive studies have disproved this assumption.” Depression was now “a highly recurrent and pernicious disorder.”³⁷

The drugs worsen the long-term course of the illness. Rather than withdraw the drugs, the profession rewrote the natural history of the illness to match the drug-damaged outcomes.

The long-term studies are unambiguous. British researchers found that never-medicated depressed patients experienced a 62 percent symptom reduction in six months; drug-treated patients, 33 percent.³⁸ A WHO study found that patients diagnosed and treated with psychiatric drugs fared worse — in both depressive symptoms and general health — over one year than those not exposed to the drugs.³⁹ In a five-year study of 9,508 depressed patients, those on antidepressants were symptomatic nineteen weeks per year, versus eleven weeks for those on no medication.⁴⁰ An NIMH study found the eighteen-month stay-well rate was highest for cognitive therapy (30 percent) and lowest for antidepressants (19 percent).⁴¹

The STAR*D trial — $35 million of NIMH money, over four thousand “real-world” patients — was announced with the claim that about 70 percent of those who stayed in the study “became symptom-free.” Ed Pigott and colleagues spent more than five years analysing the actual data. The real figure: 3 percent of patients who entered the trial remitted, stayed well, and remained in the study during the one-year follow-up. Confronted with the 3 percent number, investigator Maurizio Fava acknowledged it was accurate. The investigators had known all along.⁴²

The Patients Vote

Those 18,426 patients across Gøtzsche’s 71 trials voted with their feet. Twelve percent more chose to stop taking the drug than chose to stop taking placebo.¹ The finding is worse than it appears, because some of the patients randomised to placebo were suffering cold turkey withdrawal from drugs they had been taking before the trial. Even with this handicap, the placebo group was more willing to continue.

Gøtzsche’s team attempted to assess quality of life — the outcome that matters most to patients. The data was virtually non-existent. Out of 131 studies, three had published quality-of-life results. The data was not missing because it was not collected. It was missing because the results were unfavourable.⁴³

A Danish parliamentarian asked the Minister of Health whether it was reliable to conclude that antidepressants improved quality of life when only three of 131 studies had published data on the question. The minister referred the question to the drug agency, which replied that an effect on quality of life had been found in the studies where it was measured. Quality of life was measured in far more studies than those that published their findings.⁴⁴

What Was Not Disclosed

The feeling was real. It was produced by the natural passage of time and the body’s tendency toward spontaneous recovery. By the placebo effect of receiving treatment from an authority figure. By the enhanced placebo effect of a pill that produces noticeable physical sensations. By emotional blunting that reduced the capacity to feel distress along with the capacity to feel everything else. And in some patients, by a mild organic brain dysfunction that made the sustained experience of depression temporarily impossible.

When it came time to stop, the drug produced withdrawal symptoms indistinguishable from the original condition. Patient and doctor both interpreted this as proof that the disease had returned and the medication was needed for life. The dependence was renamed “discontinuation syndrome.”

For those who stayed on, the drug altered brain chemistry in ways that increased vulnerability to future episodes, shortened the intervals between them, and converted an episodic, self-limiting condition into a chronic one. This conversion was attributed not to the treatment but to a revised understanding of the disease. The textbooks were rewritten to match the drug-damaged outcomes.

At no point was the patient given accurate information. Not about the spontaneous remission rate. Not about the drug’s negligible advantage over placebo. Not about the blunting. Not about the withdrawal. Not about the long-term prognosis.

Three percent of STAR*D patients recovered and stayed well. The investigators announced 70 percent. Sixty-seven thousand pages of clinical trial data sat unread until one research group opened them and discovered that patients preferred placebo. Quality of life data was collected and buried. The profession was told the drugs were sensitising the brain to depression and responded that nobody was interested in investigating.

The patient was told they had a chemical imbalance. They were told the drug would correct it. They were told depression ran in their family and that they were genetically predisposed. They were told to give it a few weeks. Every element of that narrative has been contradicted by the profession’s own research.

The feeling was real. What produced it was not what they said.


References

  1. Sharma, T., et al. “Drop-out rates in placebo-controlled trials of antidepressant drugs.” Int J Risk Saf Med 30 (2019): 217–232. Discussed in Gøtzsche, P.C. “Is psychiatry a crime?” (2024), p. 21.
  2. Moncrieff, J., et al. “The serotonin theory of depression: a systematic umbrella review of the evidence.” Molecular Psychiatry (2022). See also Lacasse, J.R., Leo, J. “Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature.” PLoS Med (2005).
  3. Breggin, P.R. Toxic Psychiatry. New York: St. Martin’s Press, 1991, pp. 160–163.
  4. Deshauer, D., et al. “Selective serotonin reuptake inhibitors for unipolar depression.” Canadian Medical Association Journal 178 (2008): 1293–1301.
  5. Schuyler, D. The Depressive Spectrum. New York: Jason Aronson, 1974. Cited in Whitaker, R. Anatomy of an Epidemic. New York: Broadway Paperbacks, 2010, p. 150.
  6. Cole, J. Cited in Whitaker, Anatomy of an Epidemic, p. 150.
  7. Kline, N. Cited in Whitaker, Anatomy of an Epidemic, p. 150.
  8. Posternak, M.A., et al. “The naturalistic course of unipolar major depression in the absence of somatic therapy.” J Nerv Ment Dis 194 (2006): 324–329. Cited in Whitaker, Anatomy of an Epidemic, pp. 163–164.
  9. Schuyler, D. Cited in Whitaker, Anatomy of an Epidemic, p. 150.
  10. Posternak, J Nerv Ment Dis (2006).
  11. NIMH review of antidepressant studies. Cited in Whitaker, Anatomy of an Epidemic, p. 151.
  12. Kirsch, I., et al. “Initial severity and antidepressant benefits.” PLoS Medicine 5 (2008): e45. Cited in Whitaker, Anatomy of an Epidemic, pp. 152–153.
  13. Jakobsen, J.C., et al. “Selective serotonin reuptake inhibitors versus placebo.” BMC Psychiatry 17 (2017): 58. Leucht, S., et al. “What does the HAMD mean?” J Affect Disord 148 (2013): 243–248. Cited in Gøtzsche, “Is psychiatry a crime?” p. 19.
  14. Breggin, P.R. Toxic Psychiatry, pp. 159–160.
  15. Whitaker, Anatomy of an Epidemic, p. 151.
  16. Moncrieff, J., Wessely, S., Hardy, R. “Active placebos versus antidepressants for depression.” Cochrane Database Syst Rev (2004): CD003012.
  17. Hypericum Depression Trial Study Group. “Effect of Hypericum perforatum in major depressive disorder.” JAMA 287 (2002): 1807–1814. Cited in Whitaker, Anatomy of an Epidemic, p. 153.
  18. Gøtzsche, P.C. “Is psychiatry a crime?” (2024), p. 9.
  19. Breggin, P.R. Toxic Psychiatry, pp. 163–164.
  20. Ibid., pp. 160–161. Fisher, S. and Greenberg, R. The Limits of Biological Treatments for Psychological Distress. Hillsdale, NJ: Erlbaum, 1989.
  21. Greenberg, R., et al. Meta-analysis of newer antidepressant drugs. Cited in Breggin, P.R. Talking Back to Prozac. New York: St. Martin’s Press, 1994, pp. 89–92.
  22. Kessing, L., et al. “Depressive and bipolar disorders: patients’ attitudes and beliefs towards depression and antidepressants.” Psychological Medicine 35 (2005): 1205–1213. Cited in Gøtzsche, “Is psychiatry a crime?” p. 21.
  23. Breggin, Toxic Psychiatry, pp. 164–166.
  24. Davies, R., et al. “Confusional Episodes and Antidepressant Medication.” American Journal of Psychiatry (July 1971). Cited in Breggin, Toxic Psychiatry, pp. 165–166.
  25. Greenberg, G. Manufacturing Depression. New York: Simon & Schuster, 2010, pp. 281–282.
  26. Gøtzsche, “Is psychiatry a crime?” pp. 104–105.
  27. Rosenbaum, J.F., et al. “Selective serotonin reuptake inhibitor discontinuation syndrome.” Biol Psychiatry 44 (1998): 77–87. Analysis in Gøtzsche, “Is psychiatry a crime?” pp. 104–105. Expected relapse rate calculated from Lewinsohn, P.M., et al. J Am Acad Child Adolesc Psychiatr 33 (1994): 809–818.
  28. Greenberg, Manufacturing Depression, pp. 281–282.
  29. Breggin, P.R. Toxic Psychiatry, pp. 169–171.
  30. Law, W., III, et al. American Journal of Psychiatry (May 1981). Cited in Breggin, Toxic Psychiatry, pp. 169–170.
  31. Gøtzsche, “Is psychiatry a crime?” pp. 104–105. See also Gøtzsche, P.C. Mental Health Survival Kit and Withdrawal from Psychiatric Drugs. Ann Arbor: L H Press, 2022.
  32. Hoheisel, Schipkowensky, and others cited in Whitaker, Anatomy of an Epidemic, pp. 155–156.
  33. Van Scheyen, J.D. Cited in Whitaker, Anatomy of an Epidemic, p. 156.
  34. Fava, G. “Do antidepressant and antianxiety drugs increase chronicity in affective disorders?” Psychotherapy and Psychosomatics 61 (1994): 125–131. Fava, G. “Holding on: depression, sensitization by antidepressant drugs, and the prodigal experts.” Psychotherapy and Psychosomatics 64 (1995): 57–61. Cited in Whitaker, Anatomy of an Epidemic, pp. 157–159.
  35. Viguera, A. “Discontinuing antidepressant treatment in major depression.” Harvard Review of Psychiatry 5 (1998): 293–305. Cited in Whitaker, Anatomy of an Epidemic, p. 156.
  36. “Editorial sparks debate on effects of psychoactive drugs.” Psychiatric News, May 20, 1994. Cited in Whitaker, Anatomy of an Epidemic, p. 159.
  37. Hales, R., ed. Textbook of Psychiatry. Washington, DC: American Psychiatric Press, 1999, p. 525. Cited in Whitaker, Anatomy of an Epidemic, pp. 159–160.
  38. Ronalds, C., et al. “Outcome of anxiety and depressive disorders in primary care.” British Journal of Psychiatry 171 (1997): 427–433. Cited in Whitaker, Anatomy of an Epidemic, p. 162.
  39. Goldberg, D., et al. “The effect of detection and treatment on the outcome of major depression in primary care.” British Journal of General Practice 48 (1998): 1840–1844. Cited in Whitaker, Anatomy of an Epidemic, p. 168.
  40. Whitaker, Anatomy of an Epidemic, pp. 168–169.
  41. Shea, M.T., et al. “Course of depressive symptoms over follow-up.” Archives of General Psychiatry 49 (1992): 782–787. Cited in Whitaker, Anatomy of an Epidemic, p. 156.
  42. Pigott, H.E., et al. “Efficacy and effectiveness of antidepressants.” Psychother Psychosom 79 (2010): 267–279. Gøtzsche, “Is psychiatry a crime?” pp. 27–28.
  43. Paludan-Müller, A.S., et al. “Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants.” Int J Risk Saf Med 32 (2021): 87–99. Discussed in Gøtzsche, “Is psychiatry a crime?” pp. 21–22.
  44. Gøtzsche, “Is psychiatry a crime?” p. 22.
  45. Breggin, P.R. Talking Back to Prozac. New York: St. Martin’s Press, 1994, pp. 73–74. See also Breggin, Toxic Psychiatry, pp. 109–141 (chapter on genetics of psychiatric disorders).

April 11, 2026 Posted by | Deception, Science and Pseudo-Science, Timeless or most popular | | Comments Off on Feeling Better, Getting Worse: How Psychiatric Drugs Create the Illusion They Cure

‘Nobody Told Me’: Former Mental Health Patient Calls Out Dangerous Side Effects of Psychiatric Drugs

By Jill Erzen | The Defender | April 1, 2026

The mental health system is failing children by treating everyday struggles as “chronic illness requiring lifelong pharmaceutical treatment,” former psychiatric patient Laura Delano told lawmakers this week.

“What we are calling a mental health crisis is, in large part, a crisis of overmedicalization,” she said at a March 26 roundtable held by the U.S. House Committee on Oversight and Government Reform’s Subcommittee on Health Care and Financial Services.

Delano said many challenges people face are “rooted in nutrition, sleep, stress, trauma, substance use, relationships, vocation, environment, economics, meaning, faith and purpose.” Yet the system often reduces those issues to medical diagnoses, she said.

Drawing on her own 14 years in the mental health system, Delano told lawmakers her experience reflects a broader trend.

Now the founder of Inner Compass Initiative and author of “Unshrunk: A Story of Psychiatric Treatment Resistance,” Delano said more Americans are seeking mental healthcare than ever, but outcomes — including suicide rates among young people — continue to worsen.

‘Two meds became three, four, five. My life unraveled’

Delano said she began treatment at 13. She was diagnosed with bipolar disorder and told she would need medication for life.

“You’re told this is an incurable illness. You’ll have this for the rest of your life. It’s manageable with medications, but you will never not have it,” she said. “And that’s the story that many, many people are being told about these conditions, which is simply not true.”

Over time, her diagnoses expanded and her prescriptions multiplied.

“Two meds became three, four, five,” she said. “My life unraveled.”

She said she gained weight, developed chronic health issues and became “increasingly anxious and suicidal.”

“Eventually, I couldn’t work or take care of myself,” she said.

Delano told lawmakers her experience points to a lack of informed consent.

“Nobody told me” that many psychiatric drugs were approved based on trials lasting “on average 6 to 12 weeks,” or that the long-term effects of taking multiple drugs together have “never been properly established.”

She said she wasn’t warned that medications could cause “serious physical health problems,” impair sexual function or, in some cases, increase suicidal thoughts.

When she tried to stop taking the drugs, she said she experienced withdrawal symptoms, but was told it was a relapse.

“Nobody told me that what I experienced … was withdrawal,” she said. “Instead, I was told that my worsening state meant my illness was so severe that it was now resistant to any treatment.”

At 25, Delano said she believed there was no hope. She attempted suicide.

‘This is the next opiate crisis, and I think it’s bigger’

Delano’s testimony comes as mental health outcomes worsen, even as diagnoses and prescriptions keep rising.

From 2007 to 2021, the suicide rate among people ages 10-24 increased by 62%. In 2023, over 49,000 Americans died by suicide — the highest number on record, and about 20,000 more than in 2000.

Among adolescents in 2024, 2.6 million reported serious suicidal thoughts, 1.2 million made a plan, and 700,000 attempted suicide.

At the same time, diagnoses have surged. Today, about 23.4% of U.S. adults — roughly 61.5 million people — experienced mental illness. This includes more than 36% of young adults.

Medication use has climbed alongside those numbers.

Since 2006, the use of SSRIs in children has more than doubled. A December 2025 report found that 6.1 million U.S. children ages 17 and under are taking at least one psychiatric drug.

“This is the next opiate crisis, and I think it’s bigger,” Delano said.

Doctors are increasingly medicalizing ‘normal human unhappiness’

Other experts at the roundtable raised similar concerns about diagnosis and treatment.

Dr. Sally Satel, a psychiatrist and senior fellow at the American Enterprise Institute, said clinicians often blur the line between clinical depression and life challenges.

“I can’t tell you how many people … once got a diagnosis [of depression], but their diagnosis is really demoralization,” she said.

“Do we need medications for that?” Satel asked. In some cases, what patients need to hear is, “Your life is difficult. You’re actually having a rational response to a difficult life,” she said.

Satel also said psychiatrists do not prescribe most psychiatric medications.

Primary care providers and midlevel practitioners write many of the prescriptions, she said. “That’s definitely … a problem.”

“We are overdiagnosing,” she added. “We’re turning … normal human unhappiness into … diagnoses that we then prescribe medications for that probably won’t work.”

‘Doubling down on what we’re doing … is not going to get us anywhere’

Dr. David Hyman, a physician and legal scholar, drew a similar distinction.

“Sadness and depression are two different things,” he said. Treatment — and not necessarily with medication — should focus on the latter, he added.

He also warned against a system that increasingly defaults to prescribing. “Doubling down on what we’re doing, which isn’t working, is not going to get us anywhere better than where we are,” he said.

Hyman challenged how psychiatric drugs are evaluated over time.

While medications must show safety and efficacy to gain approval, he said, there is no consistent system to study the long-term effects or what happens when patients stop taking them.

“There’s not a mechanism or systematic reevaluation of things after they’ve been approved,” he said.

Tapering can take ‘not just months, but years’

Delano said that gap is especially clear when patients try to taper off medications.

Asked how often patients receive full information about their diagnosis and medications, she said: “From what I’ve seen, never.”

“It took 13 years to realize I needed to get out,” Delano said. But getting off the drugs is “incredibly difficult.”

“We have a system set up that makes it incredibly easy to start these drugs that were really only ever studied for … short-term use,” she said. “Yet, most people stay on them long term for years and have zero safe off-ramps.”

Without clear guidance, people often stop too quickly, feel worse and assume they need the drugs indefinitely, she said.

Delano called for updated drug labels, public education and clinical guidelines for gradual tapering.

She stressed that these medications can create physical dependence. “Not addiction, it’s different than addiction,” she said. It’s a biological effect that can make stopping difficult.

“It sounds so unfathomable that a capsule … might require chipping away … over not just months, but years,” she said. Yet for some patients, that level of gradual tapering is necessary, she added.

Now 16 years off psychiatric medications, Delano said her experience drives her work.

“It’s urgent that we better understand what is happening in people’s brains and bodies from using these medications long term and from trying to get off them,” she said.

Watch an excerpt from the subcommittee hearing here:


This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.

April 11, 2026 Posted by | Deception, Science and Pseudo-Science, Timeless or most popular | | Comments Off on ‘Nobody Told Me’: Former Mental Health Patient Calls Out Dangerous Side Effects of Psychiatric Drugs

REWRITING THE RISK? INSIDE THE GOVERNMENT’S VACCINE SAFETY MESSAGING

The HighWire with Del Bigtree | April 2, 2026

Jefferey examines newly surfaced internal communications suggesting that messaging around potential stroke risks following COVID-19 vaccination may have been altered at the highest levels of government, including the Joe Biden White House. Drawing on reported emails from federal health agencies, the segment explores how language describing a “moderately elevated” safety signal was revised to “slightly elevated,” raising serious questions about transparency, public health communication, and risk disclosure during the vaccine rollout.

The analysis also highlights how terminology shifts, from “potential risk” to “preliminary signal”, may have softened public perception of adverse events at a critical moment when booster doses were being distributed to tens of millions of Americans. With coordinated messaging efforts involving the CDC, FDA, and select media and expert networks, the discussion frames these developments as part of a broader strategy to manage public response rather than fully inform it.

Beyond stroke-related concerns, the conversation expands into other reported safety signals, including myocarditis and cardiovascular stress markers observed in certain populations following vaccination. Internal deliberations and delayed public warnings are presented as evidence of systemic gaps in adverse event reporting and physician awareness, potentially impacting early detection and response to emerging risks.

Framed within the larger debate over censorship, government accountability, and medical transparency, Jefferey raises critical questions about how public health decisions are communicated—and who ultimately controls that narrative. As scrutiny intensifies over pandemic-era policies, the discussion underscores the importance of open scientific dialogue, rigorous safety monitoring, and restoring trust in public health institutions moving forward.

April 6, 2026 Posted by | Deception, Timeless or most popular, Video | , | Comments Off on REWRITING THE RISK? INSIDE THE GOVERNMENT’S VACCINE SAFETY MESSAGING

“Davos Can Really Replace the UN”

Inside the book that maps the architecture behind global governance — from the Epstein files to the Pact for the Future

Lies are Unbekoming | April 1, 2026

On June 13, 2019, the United Nations and the World Economic Forum signed a partnership deal to “accelerate the implementation of the 2030 Agenda for Sustainable Development.” That same evening, WEF president Börge Brende — Norway’s former Foreign Minister — had dinner with Jeffrey Epstein at Epstein’s Manhattan townhouse. The Epstein files, released January 2026, contain an exchange between the two from the previous year. Epstein to Brende: “Davos can really replace the UN. C21, cyber, crypto . genetics… intl coordination.” Brende back to Epstein: “Exactly — we need a new global architecture. World Economic Forum (Davos) is uniquely positioned — public private.”

The next day, the UN General Assembly adopted the framework for restructuring global governance.

That sequence — the partnership signing, the Epstein dinner, the candid admission about replacing the UN with a public-private architecture, and then the formal adoption — opens Jacob Nordangård’s The Digital World Brain. Pages two and three. Footnoted to the UN resolution number, the Epstein files, and the General Assembly record.

I keep coming back to it because it captures what this book does that almost nothing else in the independent research space manages. I’ve followed Jacob’s work for years now and interviewed him about his research. Each book peels back another layer of the same institutional architecture, and each time I think he’s reached the limit of what can be documented, the next one goes further. Nordangård doesn’t speculate. He doesn’t editorialize much. He lays institutional actions next to each other in chronological order and lets the pattern announce itself.

The Researcher

Nordangård has a PhD in Technology and Social Change from Linköping University. Master’s degrees in geography and in culture and media production. He’s taught at three Swedish universities. His doctoral work traced how institutional networks shape EU biofuels policy — mapping the actors, the funding flows, and the coordination mechanisms that produce outcomes which look spontaneous but aren’t.

He’s been applying that same method to global governance for over a decade now, across five books. Rockefeller: Controlling the Game followed the money behind the climate agenda from the 1950s forward — Rockefeller Foundation grants to climate scientists, Rockefeller Brothers Fund involvement in virtually every major environmental conference and agreement. The Global Coup d’Etat documented the pre-existing plans that the pandemic accelerated. The Digital World Brain, first published in Swedish in 2022 and now out in an expanded English edition, takes the UN Secretary-General’s 2021 report Our Common Agenda and its twelve commitments apart, chapter by chapter, tracing the institutional genealogy behind each one.

The man also fronts a doom metal band called Wardenclyffe whose lyrics are drawn from his research. Make of that what you will.

What the Documents Actually Say

Our Common Agenda proposes twelve commitments. Read casually, they sound like boilerplate — leave no one behind, protect the planet, build trust, upgrade digital cooperation. The kind of language that slides past without friction.

Nordangård slows down and traces where each commitment came from, who drafted it, who funded the drafting, and what it requires in practice. A “new social contract” that ties your individual obligations to planetary boundaries defined by a scientific council you didn’t elect. Digital identity for every person on earth, connected to monitoring infrastructure. A Futures Lab to collect and analyse data on citizens’ attitudes, opinions, and life choices using AI. A Climate Governance Council. A Special Envoy to speak on behalf of future generations — meaning, in practice, an unelected office with a mandate to override present democratic decisions in the name of people who don’t yet exist.

Traced back through the commissions and think tanks that produced them, these twelve commitments form a three-layer governance structure. At the top, an upgraded United Nations with enforcement powers and a standing army. Beneath that, anticipatory governance — mass data collection feeding AI systems that predict behaviour and detect non-compliance. And at the base, multi-stakeholder governance: public-private partnerships implementing decisions at every level of society.

The preparatory work goes back to at least 2015, when the Albright-Gambari Commission — supported by the Stimson Center, a Washington think tank sitting at the intersection of the Council on Foreign Relations, the Trilateral Commission, and the major philanthropic foundations — recommended a World Conference on Global Institutions to coincide with the UN’s 75th anniversary in 2020.

Two months before that anniversary conference could take shape, COVID-19 shut down the world. The questions that had been prepared for member state discussions — “What are today’s most fundamental global challenges? How is the UN standing up to new challenges?” — suddenly had a very specific answer.

The New Material

This English edition adds two chapters covering events through early 2026, and they’re the reason even readers of the Swedish original need this book.

The Pact for the Future was signed at the UN Summit of the Future in September 2024. Nordangård documents the signing and the opposition — such as it was. Russia objected. But Russia’s complaint wasn’t about individual freedom or democratic accountability. It was about ensuring Russian participation as an equal partner in the new architecture. The BRICS nations voted against Russia’s procedural amendment. They didn’t want to stop the digital governance infrastructure. They just didn’t want to be junior partners in it.

The chapter called “The Great Disruptor” will unsettle people across the political spectrum, which is probably the point. Nordangård maps the network connections between the Trump administration and the very institutions Trump’s supporters believe he opposes. J.D. Vance came up through Peter Thiel’s venture capital world. Thiel sits on the Bilderberg Group’s steering committee — alongside WEF’s Börge Brende. His company Palantir was seed-funded by the CIA’s In-Q-Tel and is a partner of the WEF’s Centre for the Fourth Industrial Revolution. ICE is now using Palantir’s AI surveillance to generate “confidence scores” for tracking immigrants. Elon Musk’s grandfather ran the Canadian branch of Technocracy Inc. Musk himself was named a WEF Young Global Leader in 2008. The book includes an appendix table of Young Global Leaders with ties to the Trump administration. It runs long.

Nordangård isn’t arguing that Trump is a puppet. He’s documenting that the institutional connections run in every direction, and that what looks like opposition may be accelerating the dissolution of the old order in ways that serve the same technocratic endpoint. The evidence is specific enough that readers can evaluate it themselves.

But the most unsettling material in the new edition is a May 2025 white paper from the WEF’s Global Government Technology Centre called The Agentic State. Nordangård catches something in the title that the authors may not have intended to advertise. In psychology, the “agentic state” is Stanley Milgram’s term for the mental condition in which a person stops seeing themselves as responsible for their own actions and becomes an instrument of authority. It’s the mechanism that made ordinary people administer what they believed were lethal electric shocks in Milgram’s obedience experiments.

The white paper’s meaning is the other one — a state governed by AI agents. But the resonance hangs in the air.

The paper proposes that laws can evolve from static rules into “a far more dynamic living system, continuously interpreted, tested, and refined by agents.” Human legislators would set “broad societal goals.” Everything else — specific rules, thresholds, requirements — gets “adjusted dynamically by agents with limited or no human intervention.” Compliance becomes continuous, monitored in real time by AI systems issuing yes/no attestations across health, safety, financial, environmental, and ethics domains. Citizen input comes through “emotion detection in digital interactions” feeding into the system’s self-adjustment loops.

The authors ask what safeguards would be needed if AI agents could “issue fines or trigger legal action in real time.” They don’t answer their own question. They move on.

This isn’t a leaked memo. It’s a public white paper from a WEF-affiliated centre whose founding strategic partners include IBM, Microsoft, SAP, Oracle, and Huawei. Its lead author is the Chief Information Officer of the Estonian government. Nordangård’s contribution is placing it in the context of everything else in the book. After 250 pages of institutional genealogy, the paper reads less like futurism and more like a product specification.

The book runs 283 pages with more than 250 footnotes, a multi-page bibliography, and appendix tables cross-referencing WEF Young Global Leaders to government positions, milestones in the digital ID agenda, and the full timeline of climate governance from a 1971 MIT study through the 2024 Pact for the Future. It’s dense, and it demands an engaged reader. This is a reference work — the kind of book you come back to six months later when something shows up in the news and you want to understand which institutional thread it connects to.

Where It Comes From

The concept of a “World Brain” was articulated by H.G. Wells in 1938. Oliver Reiser, a philosophy professor at the University of Pittsburgh, developed it further through the 1940s and 1970s into a vision he called the “World Sensorium” — all of humanity integrated into a collective technological organism, governed by a World Organisation, guided by what he termed “radio-eugenics.” His book Cosmic Humanism and World Unity was published posthumously by the World Institute, which operated from offices at the United Nations Plaza in New York.

This wasn’t fringe material that got ignored. It ran directly through the Club of Rome, the Club of Budapest, the World Future Society, and into the bodies that drafted Our Common Agenda. Nordangård traces the institutional lineage. That lineage is the book’s spine.

In 1968, Columbia University professor Zbigniew Brzezinski — later US National Security Advisor, co-founder of the Trilateral Commission with David Rockefeller — wrote that new technologies could make possible “extensive population control, including the monitoring of each citizen and maintaining up-to-date files on their health or personal behaviour.” Power, he wrote, would “gravitate into those who control information and can correlate it most rapidly,” encouraging “tendencies during the next several decades toward a technocratic dictatorship, leaving less and less room for political procedures as we now know them.” That was 1968. The technology now exists to do everything Brzezinski described. The institutional architecture to deploy it is what this book documents.

The Proportionality Problem

One detail from the conclusion stays with me. Human-generated CO2 represents roughly 4% of total atmospheric carbon dioxide, which itself makes up 0.04% of the atmosphere. That comes out to about 16 parts per million. To influence a fraction of those 16 parts per million, the plan requires digitising, monitoring, tokenising, and subjecting to real-time compliance enforcement essentially everything — food production, energy, transportation, land use, individual consumption. All overseen by unelected “Planetary Stewards.”

Nordangård asks the obvious questions. How much energy will the Digital World Brain itself consume? Can the stated carbon targets be reached without measures indistinguishable from permanent authoritarian control? The white papers don’t address this.

Read the Documents

The Pact for the Future has been signed. The Global Digital Compact is annexed to it. The WHO Pandemic Agreement was adopted in May 2025. The Agentic State white paper is online for anyone to read. The UN-WEF partnership agreement is a matter of public record. The foundation funding behind the organisations that drafted all of this is disclosed in their own annual reports.

What Nordangård has done across 283 pages and more than 250 footnotes is demonstrate that these are not independent initiatives happening to converge. They are components of an architecture that has been under construction for decades, advanced by identifiable people through documented channels. He’s brought the receipts.

The book ends on a note of conviction — that this system, however carefully engineered, cannot ultimately prevail against what he calls humanity’s “natural intelligence.” Whether or not you share that faith, the institutional map he’s drawn demands a serious response. The documents are real. The signatures are dated. The timelines check out.

Read the book. Then read the documents it cites. Nordangård includes the URLs in his footnotes. You can verify every claim that matters without leaving your desk.

Then decide for yourself what a system designed to monitor every person, predict every behaviour, and enforce compliance in real time through AI agents actually is — regardless of what its architects choose to call it.

Jacob is an independent researcher doing work that no university department and no mainstream publisher would touch. He funds this through book sales and reader support. If what you’ve read here matters to you, buy the book. Give it to someone who’s starting to ask questions. This is the kind of research that deserves to find a wider audience, and that only happens when readers carry it forward.


The Digital World Brain: Our Common Agenda and The Pact for the Future by Jacob Nordangård, PhD. First English edition, 2026. Pharos Media Productions.

Get the book: pharosmedia.se

Follow Jacob’s research: drjacobnordangard.substack.com

April 6, 2026 Posted by | Book Review, Civil Liberties, Full Spectrum Dominance, Science and Pseudo-Science, Timeless or most popular | | Comments Off on “Davos Can Really Replace the UN”